UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

 ☒
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended July 29, 2023
or
 

 ☐
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___________ to ___________
 
Commission File Number 0-14818

KASPIEN HOLDINGS INC.
 
(Exact Name of Registrant as Specified in its Charter)
 
New York
  
14-1541629
State or Other Jurisdiction of Incorporation or Organization
  
I.R.S. Employer Identification No.
     
2818 N. Sullivan Rd. Ste 130
Spokane Valley, WA
  
99216
Address of Principal Executive Offices
  
Zip Code
 
(509)-900-6287
Registrant’s Telephone Number, Including Area Code

 
Former Name, Former Address and Former Fiscal Year, if Changed Since Last Report
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, $.01 par value per share
KSPN
 OTCQB

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒    No ☐
 
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒    No ☐
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
 
Large accelerated filer ☐
Accelerated filer ☐
Non-accelerated filer ☒
Smaller reporting company ☒
 
Emerging growth company ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐  
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).  Yes ☐     No ☒
 
APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
 
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.      Yes ☐    No ☐

APPLICABLE ONLY TO CORPORATE ISSUERS

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

Common Stock, $.01 par value,
4,969,738 shares outstanding as of September 10, 2023
Kaspien Holdings Inc.
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
QUARTERLY REPORT ON FORM 10-Q
INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

 
Form 10-Q
Page No.
PART I. FINANCIAL INFORMATION
 
 
 
Item 1 – Interim Condensed Consolidated Financial Statements (Unaudited)
 
 
 
4
 
 
5
 
 
6
 
 
7
 
 
8
 
 
9
 
 
22
 
 
29
 
 
29
 
 
PART II.  OTHER INFORMATION
 
 
 
30
 
 
30
 
 
30
 
 
30
 
 
30
 
 
30
 
 
31
 
 
32

2
FORWARD-LOOKING STATEMENTS

This quarterly report on Form 10-Q contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, particularly in the discussion under the caption “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” All statements other than statements of historical fact are forward-looking. Examples of forward-looking statements include, but are not limited to, statements regarding our ability to achieve profitability and meet future liquidity needs and capital requirements, future business, future results of operations or financial condition, and our business strategies. You can identify many forward-looking statements by words such as “may,” “will,” “would,” “should,” “could,” “expect,” “aim,” “anticipate,” “believe,” “estimate,” “intend,” “plan,” “predict,” “project,” “seek,” “potential,” “opportunities” and other similar expressions and the negatives of such expressions. However, not all forward-looking statements contain these words. Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from those expressed or implied by the forward-looking statements contained herein. Such risks and uncertainties include, among others, those risks discussed under the caption “Risk Factors” in our most recently filed Annual Report on Form 10‑K, which was filed with the Securities and Exchange Commission (the “SEC”) on April 28, 2023 (the “2022 Form 10-K”), and in our consolidated financial statements, related notes, and the other information appearing elsewhere in the 2022 Form 10‑K, this quarterly report on Form 10-Q and our other filings with the SEC. Given these risks and uncertainties, you should not place undue reliance on any forward-looking statements. The forward-looking statements contained in this quarterly report on Form 10-Q are made only as of the date hereof, and we do not intend, and, except as required by law, we undertake no obligation to update any forward-looking statements contained herein after the date of this report to reflect actual results or future events or circumstances.

3
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION
Item 1 - Interim Condensed Consolidated Financial Statements
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except per share and share amounts)
(unaudited)

   
July 29,
    
January 28,
    
July 30,
  
   
2023
    
2023
    
2022
  
ASSETS  
Unaudited
          
Unaudited
  
CURRENT ASSETS
                  
Cash and cash equivalents
  
$
282
    
$
1,130
    
$
1,309
  
Restricted cash
    
1,158
      
1,158
      
1,158
  
Accounts receivable
    
2,211
      
1,969
      
2,082
  
Merchandise inventory
    
26,055
      
26,704
      
29,363
  
Prepaid expenses and other current assets
    
620
      
999
      
618
  
Total current assets
    
30,326
      
31,960
      
34,530
  
                         
Restricted cash
    
1,315
      
1,338
      
1,873
  
Fixed assets, net
    
1,769
      
1,999
      
2,357
  
Operating lease right-of-use assets
    
1,181
      
1,505
      
1,823
  
Cash Surrender Value
    
3,652
      
3,371
      
3,768
  
Other assets
    
566
      
566
      
777
  
TOTAL ASSETS
  
$
38,809
    
$
40,739
    
$
45,128
  
                         
LIABILITIES
                        
CURRENT LIABILITIES
                        
Accounts payable
  
$
8,196
    
$
7,044
    
$
8,012
  
Short-term borrowings
    
8,797
      
8,812
      
3,855
  
Short-term debt
     11,082       -       -  
Accrued expenses and other current liabilities
    
2,291
      
2,876
      
1,753
  
Current portion of operating lease liabilities
    
689
      
695
      
550
  
Total current liabilities
    
31,055
      
19,427
      
14,170
  
                         
Operating lease liabilities
    
727
      
1,019
      
1,416
  
Long-term debt
    
-
      
9,790
      
8,548
  
Other long-term liabilities
    
11,308
      
11,604
      
13,788
  
TOTAL LIABILITIES
    
43,090
      
41,840
      
37,922
  
                         
SHAREHOLDERS’ EQUITY (DEFICIT)
                        
Preferred stock  ($0.01 par value; 5,000,000 shares authorized; none issued)
    
-
      
-
      
-
  
Common stock ($0.01 par value; 200,000,000 shares authorized; 5,432,072, 5,432,072 and 3,911,985 shares issued, respectively)
    
54
      
54
      
39
  
Additional paid-in capital
    
214,161
      
214,029
      
263,723
  
Treasury stock at cost (467,069, 467,069 and 1,410,378 shares, respectively)
    
(76,132
)
    
(76,132
)
    
(125,906
)
Accumulated other comprehensive loss
    
886
      
886
      
(910
)
Accumulated deficit
    
(143,250
)
    
(139,938
)
    
(129,740
)
TOTAL SHAREHOLDERS’ EQUITY (DEFICIT)
    
(4,281
)
    
(1,101
)
    
7,206
  
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY (DEFICIT)
  
$
38,809
    
$
40,739
    
$
45,128
  

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

4
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(amounts in thousands)
(unaudited)

   
Thirteen Weeks Ended
    
Twenty-Six Weeks Ended
  
   
July 29,
    
July 30,
    
July 29,
    
July 30,
 
    2023
    2022     2023
     2022
  
                         
Net revenue
  
$
33,136
    
$
33,907
     $ 66,068     $ 65,697  
                                 
Cost of sales
    
25,818
      
27,178
       51,297       52,118  
Gross profit
    
7,318
      
6,729
       14,771       13,579  
Selling, general and administrative expenses
    
8,251
      
10,201
       16,961       20,719  
Loss from operations
    
(933
)
    
(3,472
)
     (2,190 )     (7,140 )
Interest expense
    
954
      
901
       1,848       1,663  
Other income
     (777 )     -       (777 )     -  
Loss before income tax expense
    
(1,110
)
    
(4,373
)
     (3,261 )     (8,803 )
Income tax expense
    
51
      
43
       51       43  
Net loss
  

(1,161
)
  

(4,416
)
  
(3,312 )  
(8,846 )
BASIC AND DILUTED LOSS PER SHARE:
                                
Basic and diluted loss per common share
   $ (0.23 )   $ (1.69 )   $ (0.67 )   $ (3.47 )
Weighted average number of common shares outstanding – basic and diluted
     4,965       2,613       4,965       2,553  

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

5
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(amounts in thousands)
(unaudited)

   
Thirteen Weeks Ended
     Twenty-Six Weeks Ended
  
   
July 29,
    
July 30,
    
July 29,
   
July 30,
 
    2023
     2022
     2023
     2022
  
                         
Net loss
  
$
(1,161
)
  
$
(4,416
)
   $ (3,312 )   $ (8,846 )
Amortization of pension gain
    
-
      
-
       -       -  
Comprehensive loss
  
$
(1,161
)
  
$
(4,416
)
   $ (3,312 )   $ (8,846 )

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

6
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS’ EQUITY
(dollars and shares in thousands)
(unaudited)

  Thirteen Weeks Ended July 29, 2023  
 
Number of shares outstanding
              
Accumulated
  
Retained
      
             
Additional
  
Treasury
  
Other
  
Earnings
      
 
Common
  
Treasury
  
Common
  
Paid-in
  
Stock
  
Comprehensive
  
(Accumulated
  
Shareholders’
  
 
Shares
  
Shares
  
Stock
  
Capital
  
At Cost
  
Loss
  
Deficit)
  
Equity (Deficit)
  
Balance as of April 29, 2023
    
5,432
      
(467
)
  
$
54
    
$
214,092
    
$
(76,132
)
  
$
886
    
$
(142,089
)
  
$
(3,189
)
Net Loss
    
-
      
-
      
-
      
-
      
-
      
-
      
(1,161
)
    
(1,161
)
Amortization of unearned compensation/restricted stock amortization
    
-
      
-
      
-
      
69
      
-
      
-
      
-
      
69
  
Balance as of July 29, 2023
    
5,432
     $
(467
)
  
$
54
    
$
214,161
    
$
(76,132
)
  
$
886
    
$
(143,250
)
  
$
(4,281
)

 
Twenty-six Weeks Ended July 29, 2023
  
 
Number of shares outstanding
              
Accumulated
  
Retained
      
             
Additional
  
Treasury
  
Other
  
Earnings
      
 
Common
  
Treasury
  
Common
  
Paid-in
  
Stock
  
Comprehensive
  
(Accumulated
  
Shareholders’
  
 
Shares
  
Shares
  
Stock
  
Capital
  
At Cost
  
Loss
  
Deficit)
  
Equity (Deficit)
  
Balance as of January 28,2023
    
5,432
      
(467
)
  
$
54
    
$
214,029
    
$
(76,132
)
  
$
886
    
$
(139,938
)
  
$
(1,101
)
Net Loss
    
-
      
-
      
-
      
-
      
-
      
-
      
(3,312
)
    
(3,312
)
Amortization of unearned compensation/restricted stock amortization
    
-
      
-
      
-
      
132
      
-
      
-
      
-
      
132
  
Balance as of July 29, 2023
    
5,432
     $
(467
)
  
$
54
    
$
214,161
    
$
(76,132
)
  
$
886
    
$
(143,250
)
  
$
(4,281
)

 
Thirteen Weeks Ended July 30, 2022
  
 
Number of shares outstanding
              
Accumulated
  
Retained
      
             
Additional
  
Treasury
  
Other
  
Earnings
      
 
Common
  
Treasury
  
Common
  
Paid-in
  
Stock
  
Comprehensive
  
(Accumulated
  
Shareholders’
  
 
Shares
  
Shares
  
Stock
  
Capital
  
At Cost
  
Loss
  
Deficit)
  
Equity
  
Balance as of April 30, 2022
    
3,903
      
(1,410
)
  
$
39
    
$
360,738
    
$
(230,170
)
  
$
(910
)
  
$
(125,324
)
  
$
4,375
  
Net income
    
-
      
-
      
-
      
-
      
-
      
-
      
(4,416
)
    
(4,416
)
Issuance of shares, net of expenses
     -       638       -       (97,127 )     104,264       -       -       7,137  
Common stock issued- Director grants
     9       -       -       41       -       -       -       41  
Amortization of unearned compensation/restricted stock amortization
    
-
      
-
      
-
      
71
      
-
      
-
      
-
      
71
  
Balance as of July 30, 2022
    
3,912
     $
(772
)
  
$
39
    
$
263,723
    
$
(125,906
)
  
$
(910
)
  
$
(129,740
)
  
$
7,206
  

 
Twenty-six Weeks Ended July 30, 2022
  
 
Number of shares outstanding
              
Accumulated
  
Retained
      
             
Additional
  
Treasury
  
Other
  
Earnings
      
 
Common
  
Treasury
  
Common
  
Paid-in
  
Stock
  
Comprehensive
  
(Accumulated
  
Shareholders’
  
 
Shares
  
Shares
  
Stock
  
Capital
  
At Cost
  
Loss
  
Deficit)
  
Equity
  
Balance as of January 29, 2022
    
3,903
      
(1,410
)
  
$
39
    
$
359,220
    
$
(230,170
)
  
$
(910
)
  
$
(120,894
)
  
$
7,285
  
Net Loss
    
-
      
-
      
-
      
-
      
-
      
-
      
(8,846
)
    
(8,846
)
Issuance of shares, net of expenses
     -       638       -       (97,127 )     104,264       -       -       7,137  
Issuance of warrants
     -       -       -       1,518       -       -       -       1,518  
Common stock issued- Director grants
    9       -       -       41       -       -       -       41  
Amortization of unearned compensation/restricted stock amortization
    
-
      
-
      
-
      
71
      
-
      
-
      
-
      
71
  
Balance as of July 30, 2022
    
3,912
      
(772
)
  
$
39
    
$
263,723
    
$
(125,906
)
  
$
(910
)
  
$
(129,740
)
  
$
7,206
  

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

7
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
(unaudited)

    Twenty-Six Weeks Ended
  
   
July 29,
    
July 30,
  
    2023
     2022
  
OPERATING ACTIVITIES:
            
Net loss
  
$
(3,312
)
  
$
(8,846
)
Adjustments to reconcile net loss to net cash used in operating activities:
                
Depreciation of fixed assets
    
366
      
594
  
Amortization of intangible assets
     -       -  
Stock-based compensation
    
133
      
112
  
Amortization of ROU asset
     325       321  
Amortization of warrant interest
     524       612  
Interest on long term debt
    
768
      
389
  
Change in cash surrender value
    
(281
)
    
386
  
Changes in operating assets and liabilities that provide (use) cash:
                
Accounts receivable
    
(242
)
    
253
  
Merchandise inventory
    
649
      
(86
)
Prepaid expenses and other current assets
    
379
      
32
  
Other long-term assets
    
-
      
188
  
Accounts payable
    
1,152
      
1,740
  
Accrued expenses and other current liabilities
    
(591
)
    
(999
)
Other long-term liabilities
    
(589
)
    
(589
)
Net cash used in operating activities
    
(719
)
    
(5,893
)
                 
INVESTING ACTIVITIES:
                
Purchases of fixed assets
     (137 )     (616 )
Net cash provided by (used in) investing activities
     (137 )     (616 )
                 
FINANCING ACTIVITIES:
                
Payments of short term borrowings
     (15 )     (6,111 )
Proceeds from long term borrowings
    
-
      
5,000
  
Proceeds from issuance of shares, net of expense
     -       7,137  
Net cash provided by (used in) financing activities
    
(15
)
    
6,026
  
                 
Net increase (decrease) in cash, cash equivalents, and restricted cash
    
(871
)
    
(483
)
Cash, cash equivalents, and restricted cash, beginning of period
    
3,626
      
4,823
  
Cash, cash equivalents, and restricted cash, end of period
  
$
2,755
    
$
4,340
  
                 
Supplemental disclosures and non-cash investing and financing activities:
               
Interest paid
  $ 543     $ 386  
Warrants issued with debt
  $
-     $
1,633  

See Accompanying Notes to Interim Condensed Consolidated Financial Statements.

8
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (unaudited)
July 29, 2023 and July 30, 2022
Note 1. Nature of Operations

Kaspien Holdings Inc., which, together with its consolidated subsidiaries, is referred to herein as “Kaspien”, “the Company”, “we”, “us” and “our”, was incorporated in New York in 1972. We own 100% of the outstanding common stock of Kaspien Inc, through which our principal operations are conducted. Kaspien is a third-party marketplace retailer. The Company leverages in-house expertise, technology, and services to generate revenue through marketplace transactions. Kaspien provides account management, brand development, listings management, data reporting, joint business planning, and comprehensive marketing support services to our vendor partners.  Our target partners are enterprise-level large growth brands that derive margins based on pricing.

We are guided by 5 core principles:

•
We are partner obsessed. Our customers are our partners. Every decision is focused on building mutually beneficial relationships that deliver results.

•
We are insights driven. We make data actionable. Our curiosity drives us to discover opportunities early and often.

•
We create simplicity. We challenge the status quo. We take the complicated and simplify it.

•
We take ownership. We make things happen. We hold ourselves accountable and have a bias for action.

•
We empower each other. We welcome and learn from diverse experiences. Our empathy ignites innovation and empowers meaningful change.

On June 6, 2023, Kaspien entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which Kaspien sold substantially all of the assets of and certain of the liabilities relating to Kaspien’s agency business model through which Kaspien provides support services for account management, media planning, media analytics, search strategy, business planning, and data reporting to its partners (the “Business” and the transaction, the “Transaction”). The Transaction closed on June 6, 2023.

Liquidity and Cash Flows:

The Company’s primary sources of liquidity are its borrowing capacity under its Credit Facility, available cash and cash equivalents, and to a lesser extent, cash generated from operations. Our cash requirements relate primarily to working capital needed to operate Kaspien, including funding operating expenses, the purchase of inventory and capital expenditures.
 
The Company incurred a net loss of $3.3 million and $8.8 million for the twenty-six weeks ended July 29, 2023 and July 30, 2022, respectively.  The decrease in the net loss was primarily attributable to a decrease in sales and gross margin. In addition, the Company has an accumulated deficit of $143.3 million as of July 29, 2023 and net cash used in operating activities for the twenty-six weeks ended July 29, 2023 was $0.7 million. Net cash used in operating activities for the twenty-six weeks ended July 30, 2022 was $5.9 million.

As disclosed in the Company’s Annual Report on Form 10-K filed April 28, 2023, the Company experienced negative cash flows from operations during fiscal 2022 and 2021 and we expect to incur net losses in fiscal 2023.

9
Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; and successful implementation of our strategy and planned activities. There can be no assurance that we will be successful in further implementing our business strategy or that the strategy, including the completed initiatives, will be successful in sustaining acceptable levels of sales growth and profitability. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The unaudited condensed consolidated financial statements for the twenty-six weeks ended July 29, 2023 were prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ability of the Company to meet its liabilities and to continue as a going concern is dependent on improved profitability, the strategic initiatives for Kaspien and the availability of future funding. Based on recurring losses from operations, negative cash flows from operations, the expectation of continuing operating losses for the foreseeable future, and uncertainty with respect to any available future funding, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As of July 29, 2023, we had cash and cash equivalents of $0.3 million, a net working deficit of $0.7 million, and $8.8 in borrowings on our revolving credit facility, as further discussed below.

As of January 28, 2023, the Company had borrowings of $8.8 million under the Credit Facility. As of April 29, 2023 and April 30, 2022, the Company had no outstanding letters of credit. The Company had $3.4 million and $7.7 million available for borrowing under the Credit Facility as of  July 29, 2023 and July 30, 2022, respectively.

Credit Facility
On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

On March 30, 2020, the Company and Kaspien Inc. (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.


On April 7, 2021, the Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

10
On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the Credit Facility was extended to February 20, 2024, and the early termination fees were accordingly reset; (ii) the LIBOR floor was reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.


On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (the “Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).



On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the loan agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of July 29, 2023 and July 30, 2022, the Company had borrowings of $8.8 and $3.9 million under the Credit Facility, respectively.

Subordinated Debt Agreement
On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien with a scheduled maturity date of May 22, 2023. As of July 29, 2023, unamortized debt issuance costs of $0.1 million are included in “Long Term Debt” on the unaudited condensed consolidated balance sheet.

Directors Jonathan Marcus, Thomas Simpson, and Michael Reickert are the chief executive officer of Alimco Re Ltd. (“Alimco”), the managing member of Kick-Start III, LLC and Kick-Start IV, LLC (“Kick-Start”), and a trustee of the Robert J. Higgins TWMC Trust (the “Trust”), an affiliate of RJHDC, LLC (“RJHDC” and together with Alimco and Kick-Start, “Related Party Entities”), respectively.  The Related Party Entities are parties to the Subordinated Loan Agreement.


Amendment No. 2 to Subordinated Loan and Security Agreement



On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) with the “Lenders and the Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.

11

The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.



Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.


The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.


The Loan Parties paid certain customary fees and expenses in connection with the Additional Subordinated Loan and Amendment No. 2.


In addition to the aforementioned current sources of existing working capital, the Company may explore certain other strategic alternatives that may become available to the Company, as well continuing our efforts to generate additional sales and increase margins. However, at this time the Company has no commitments to obtain any additional funds, and there can be no assurance such funds will be available on acceptable terms or at all, should we require such additional funds. If the Company is unable to improve its operations, it may be required to obtain additional funding, and the Company’s financial condition and results of operations may be materially adversely affected.

Furthermore, broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance, and may adversely impact our ability to raise additional funds, should we require such additional funds.

Note 2. Basis of Presentation

The accompanying interim condensed consolidated financial statements consist of Kaspien Holdings Inc., its wholly owned subsidiaries, Kaspien NY, LLC (f/k/a Trans World NY Sub, Inc. (f/k/a Record Town, Inc.)) and its subsidiaries, and Kaspien, Inc. All intercompany accounts and transactions have been eliminated.

The interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited interim condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to rules and regulations applicable to interim financial statements.

12
The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the year ended January 28, 2023 contained in the Company’s Annual Report on Form 10-K filed April 28, 2023.  The results of operations for the thirteen weeks ended July 29, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ending February 3, 2024.

The Company’s significant accounting policies are the same as those described in Note 1 to the Company’s Consolidated Financial Statements on Form 10-K for the fiscal year ended January 28, 2023.

Note 3. Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost. The model replaces the probable, incurred loss model for those assets and instead, broadens the information an entity must consider in developing its expected credit loss estimate for assets measured at amortized cost. This standard will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022. We have completed our evaluation and have determined that the update will not have a material impact on our consolidated financial condition, results of operations, or cash flows.

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 provides, among other things, guidance that modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate; modifications of contracts within the scope of Topic 840, Leases, should be accounted for as a continuation of the existing contract; and, changes in the critical terms of hedging relationships, caused by reference rate reform, should not result in the de-designation of the instrument, provided certain criteria are met. The Company’s exposure to LIBOR rates includes its credit facility. The amendments are effective as of March 12, 2020 through December 31, 2022. We have completed our evaluation and have determined that the update will not have a material impact on our consolidated financial condition, results of operations, or cash flows.

Recent accounting pronouncements pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.

Note 4. Depreciation and Amortization

Depreciation and amortization included in selling, general and administrative expenses of the interim condensed consolidated statements of operations for the thirteen weeks ended July 29, 2023 and July 30, 2022 was $0.2 million and $0.3 million, respectively.

Depreciation and amortization included in selling, general and administrative expenses of the interim condensed consolidated statements of operations for the twenty-six weeks ended July 29, 2023 and July 30, 2022 was $0.4 million and $0.6 million, respectively.

13
Note 5. Restricted Cash

As a result of the death of its former Chairman, the Company holds $2.5 million in a rabbi trust, of which $1.2 million is classified as restricted cash in current assets and $1.3 million is classified as restricted cash in other assets on the accompanying interim condensed consolidated balance sheet as of July 29, 2023.

A summary of cash, cash equivalents and restricted cash is as follows (amounts in thousands):

   
July 29,
    
January 28,
    
July 30,
  
     2023     2023     2022
 
Cash and cash equivalents
  
$
282
    
$
1,130
    
$
1,309
  
Restricted cash
    
2,473
      
2,496
      
3,031
  
Total cash, cash equivalents and restricted cash
  
$
2,755
    
$
3,626
    
$
4,340
  

Note 6.  Debt

Credit Facility
On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

The commitments by the lenders under the Credit Facility are subject to borrowing base and availability restrictions. Up to $5.0 million of the Credit Facility may be used for the making of swing line loans.

Interest under the Credit Facility accrues, subject to certain terms and conditions under the Loan Agreement, at a SOFR Rate or Base Rate, plus, in each case, an Applicable Margin, which is determined by reference to the level of Availability as defined in the Loan Agreement, with the Applicable Margin for SOFR Rate loans ranging from 4.00% to 4.50% and the Applicable Margin for Base Rate loans ranging from 3.00% to 3.50%.

The Credit Facility is secured by a first priority security interest in substantially all of the assets of Kaspien, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Credit Facility (collectively, the “Credit Facility Parties”) and by a first priority pledge by the Company of its equity interests in Kaspien. The Company will provide a limited guarantee of Kaspien’s obligations under the Credit Facility.

Among other things, the Loan Agreement limits Kaspien’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets. The Loan Agreement also requires Kaspien to comply with a financial maintenance covenant.

The Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the Credit Facility Parties taken as a whole, the occurrence of an uninsured loss to a material portion of collateral and failure of the obligations under the Credit Facility to constitute senior indebtedness under any applicable subordination or intercreditor agreements.

On March 30, 2020, the Company and Kaspien (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan

14
Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.
 
On April 7, 2021, Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the Credit Facility was extended to February 20, 2024, and the early termination fees were accordingly reset; (ii) the LIBOR floor was reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.

On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (“Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).

On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the Loan Agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of July 29, 2023, the Company had borrowings of $8.8 million under the Credit Facility. The Company had borrowings of $3.9 million as of July 30, 2022. As of July 29, 2023, unamortized debt issuance costs of $0.1 million related to the Credit Facility are included in Other assets on the unaudited condensed consolidated balance sheet.

The Company records short term borrowings at cost, in which the carrying value approximates fair value due to its short-term maturity.

Subordinated Loan Agreement

On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien. On September 17, 2021, the Loan Parties entered into Amendment No. 1 to the Subordinated Loan Agreement which extended the maturity of the loan to March 31, 2024. As of October 29, 2022, unamortized debt issuance costs of $0.1 million are included in “Long-Term Debt” on the consolidated balance sheet.

Interest on the Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of twelve percent (12.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Subordinated Loan.

The Subordinated Loan is secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement (collectively, the “Second Lien Credit Facility Parties”). The Company will provide a limited guarantee of Kaspien ’s obligations under the Subordinated Loan.

15
Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.
 
The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the Second Lien Credit Facility Parties taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.
 
In conjunction with the Subordinated Debt Agreement, the Company issued warrants to purchase up to 244,532 shares of Common Stock to the Related Party Entities (127,208 shares for Alimco, 23,401 shares for Kick-Start, and 93,923 shares for RJHDC), subject to adjustment in accordance with the terms of the Warrants, at an exercise price of $0.01 per share. As of July 29, 2023, 5,126 warrants remain outstanding.

The value of the warrants of $0.8 million was allocated against the principal proceeds of the Subordinated Debt Agreement, $0.1 million of which was unamortized as of July 29, 2023.

On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) the “Lenders and Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.

The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

16
In conjunction with the Subordinated Debt Agreement, the Company issued warrants to purchase up to warrants to purchase up to 320,000 shares of common stock of the Company (subject to adjustment in accordance with the terms of the Warrants, the “Warrant Shares”) at an exercise price of $0.01 per share.  The Warrants are exercisable during the period commencing on March 2, 2022 and ending on the earlier of (a) 5:00 p.m. Eastern Standard Time on the five (5)-year anniversary thereof, or if such day is not a business day on the next succeeding business day, or (b) the occurrence of certain consolidations, mergers or similar extraordinary events involving the Company. As of October 29, 2022, all of the warrants remain outstanding.
 
The value of the warrants of $1.6 million was allocated against the principal proceeds of the Subordinated Debt Agreement, of which $0.6 million was unamortized as of July 29, 2023. The value of the warrants was recognized as a discount based on the relative fair value of the consideration received, as an offset to APIC, which will be amortized over the life of the loan.

Note 7. Stock Based Compensation

The Company has outstanding awards under four employee stock award plans: the 2005 Long Term Incentive and Share Award Plan; the Amended and Restated 2005 Long Term Incentive and Share Award Plan; the 2005 Long Term Incentive and Share Award Plan (as amended and restated April 5, 2017 (the “Old Plans”); and Kaspien Holdings Inc. 2005 Long Term Incentive and Share Award Plan (as amended and restated on August 2, 2022) (the “New Plan”). Collectively, these plans are referred to herein as the Stock Award Plans. The Company no longer issues stock options under the Old Plans.

Equity awards authorized for issuance under the New Plan total 500,000.  As of July 29, 2023, of the awards authorized for issuance under the Stock Award Plans, approximately 195,005 were granted and are outstanding, 35,042 of which were vested and exercisable. Shares available for future grants of options and other share-based awards under the New Plan as of January 28, 2023 were 391,137.
The following table summarizes stock award activity during the thirteen weeks ended July 29, 2023:

    Employee Stock Award Plans
 
   
Number of
Shares
Subject To
Option
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
Term
   
Other
Share
Awards (1)
    
Weighted
Average
Grant Fair
Value
 
Balance January 28, 2023
    
123,642
    
$
6.00
      
7.5
       19,500
     $ 18.35  
Granted
    
-
      
-
      
-
       60,000       0.61  
Forfeited
    
(7,637
)
    
(9.01
)
    
-
       -       -  
Canceled
    
(500
)
    
(97.40
)
    
-
       -       -  
Exercised
    
-
      
-
      
-
       -       -  
Balance July 29, 2023
    
115,505
    
$
5.79
      
8.4
       79,500     $ 4.96  
Exercisable July 29, 2023
    
35,042
    
$
13.37
      
7.0
       -       -  

 (1) Other Share Awards include deferred shares granted to executives and directors.

As of July 29, 2023, the intrinsic value of stock awards outstanding and stock awards exercisable was $0.

Note 8. Shareholders’ Equity (Deficit)

17
On July 12, 2022, the Company entered into a Securities Purchase Agreement (the “PIPE Purchase Agreement”) with a single institutional investor for a private placement offering (“Private Placement”) of the Company’s common stock (the “Common Stock”) or pre-funded warrants, with each pre-funded warrant exercisable for one share of Common Stock (the “Pre-Funded Warrants”), and warrants exercisable for one share of Common Stock (the “Investor Warrants”). Pursuant to the PIPE Purchase Agreement, the Company has agreed to issue and sell 1,818,182 shares (the “Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof together with Investor Warrants to purchase up to 2,457,160 shares of Common Stock. Each share of Common Stock and accompanying Investor Warrant will be sold together at a combined offering price of $3.30 per share.

As of July 29, 2023 all of the Prefunded Warrants were exercised in full.

The Investor Warrants have an exercise price of $3.13 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. The Investor Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

The Private Placement closed on July 14, 2022. The Company received approximately $6 million in gross proceeds from the Private Placement, before deducting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

On July 12, 2022, the Company also entered into a Securities Purchase Agreement (the “Registered Purchase Agreement”) with a single institutional investor, pursuant to which the Company agreed to issue and sell 638,978 shares (the “Registered Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof, with each Pre-Funded Warrant exercisable for one share of Common Stock (the “Offering”). The Company received approximately $2 million in gross proceeds from the Offering, before deducting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

Net proceeds from the Private Placement and the Offering, after deducting placement agent fees and other estimated offering expenses payable by the Company of $0.9 million, were approximately $7.1 million.

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, as of April 29, 2023:
Exercise
    
Number
  
Price
    
Outstanding
  
$
0.01
      
325,126
  
$
3.13
      
2,457,160
  
         
2,782,286
  

There were no warrant transactions during the quarter and the weighted average exercise price for the outstanding warrants is $2.77. As of July 29, 2023, the intrinsic value of the warrants was $60,000 with a weighted average remaining term of 4 years.

Note 9. Accumulated Other Comprehensive Loss

Accumulated other comprehensive loss that the Company reports in the interim condensed consolidated balance sheets represents net loss, adjusted for the difference between the accrued pension liability and accrued benefit cost, net of taxes, associated with the Company’s defined benefit plan. Comprehensive loss consists of net loss for all periods presented.

18


Note 10. Defined Benefit Plan



The Company maintains a non-qualified Supplemental Executive Retirement Plan (“SERP”) for certain executive officers of the Company.  The SERP provides eligible executives defined pension benefits that supplement benefits under other retirement arrangements.  As of February 28, 2020, no active employees were participants in the SERP. During the thirteen weeks ended July 29, 2023, the Company did not make any cash contributions to the SERP and presently expects to pay approximately $1.2 million in benefits relating to the SERP during fiscal 2023.



The measurement date for the SERP is the fiscal year end, using actuarial techniques which reflect estimates for mortality, turnover and expected retirement. In addition, management makes assumptions concerning future salary increases. Discount rates are generally established as of the measurement date using theoretical bond models that select high-grade corporate bonds with maturities or coupons that correlate to the expected payouts of the applicable liabilities.

 

The following represents the components of the net periodic pension cost related to the Company’s SERP for the respective periods:


   
Thirteen Weeks Ended
    
Twenty-six Weeks Ended
  
(amounts in thousands)
 
July 29,
    
July 30,
    
July 29,
    
July 30,

  2023
     2022
     2023
     2022
  
                         
Interest cost
  
$
139
    
$
89
    
$
278
    
$
178
  
Net periodic pension cost
  
$
139
    
$
89
    
$
278
    
$
178
  

Note 11. Basic and Diluted Loss Per Share

Basic loss per share is calculated by dividing net loss by the weighted average common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock (net of any assumed repurchases) that then shared in the earnings of the Company, if any.  It is computed by dividing net loss by the sum of the weighted average shares outstanding and additional common shares that would have been outstanding if the dilutive potential common shares had been issued for the Company’s common stock awards from the Company’s Stock Award Plans.

For the thirteen-week and twenty-six week periods ended July 29, 2023 and July 30, 2022, the impact of all outstanding stock awards was not considered because the Company reported net losses in those periods and such impact would be anti-dilutive.  Accordingly, basic and diluted loss per share was the same.  Total anti-dilutive stock awards for the thirteen and twenty-six weeks ended July 29, 2023 and thirteen and twenty-six weeks ended July 29, 2023 were approximately 0.1 million shares for all periods.

Total anti-dilutive warrants for the thirteen weeks and twenty-six week periods ended July 29, 2023 were approximately 2.8 million shares for both periods.

19

Note 12. Income Taxes

In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent on the generation of future taxable income. Management considers the scheduled reversal of taxable temporary differences, projected future taxable income and tax planning strategies in making this assessment.  Based on available objective evidence, management concluded that a full valuation allowance should continue to be recorded against the Company’s deferred tax assets. Management will continue to assess the need for and amount of the valuation allowance against the deferred tax assets by considering all available evidence to the Company’s ability to generate future taxable income in its conclusion of the need for a full valuation allowance.  Any reversal of the Company’s valuation allowance will favorably impact its results of operations in the period of reversal.  The Company is currently unable to determine whether or when that reversal might occur, but it will continue to assess the realizability of its deferred tax assets and will adjust the valuation allowance if it is more likely than not that all or a portion of the deferred tax assets will become realizable in the future.  The Company has significant net operating loss carry forwards and other tax attributes that are available to offset projected taxable income and current taxes payable, if any, for the year ending January 28, 2023.  The deferred tax impact resulting from the utilization of the net operating loss carry forwards and other tax attributes will be offset by a reduction in the valuation allowance. As of January 28, 2023, the Company had a net operating loss carry forward of $369.1 million for federal income tax purposes and approximately $224.4 million for state income tax purposes that expire at various times through 2040 and are subject to certain limitations and statutory expiration periods.  The Company has not changed its overall conclusion with respect to the need for a valuation allowance against its net deferred tax assets, which remain fully reserved.

Note 13. Commitments and Contingencies

Legal Proceedings

The Company is subject to legal proceedings and claims that have arisen in the ordinary course of its business and have not been finally adjudicated.  Although there can be no assurance as to the ultimate disposition of these matters, it is management’s opinion, based upon the information available at this time, that the expected outcome of these matters, individually and in the aggregate, will not have a material adverse effect on the results of operations and financial condition of the Company. As a result, the liability for the cases listed below is remote.

On June 18, 2021, Vijuve Inc. filed a lawsuit against Kaspien Inc. in the United States District Court for the Eastern District of Washington (Case No. 2:21-cv-00192-SAB) concerning a Retailer Agreement that the parties entered into in September of 2020. Vijuve manufactures skin care products and face massagers. The parties agreed that Kaspien would sell Vijuve’s products on Amazon. The complaint alleged that Kaspien breached the Retailer Agreement when it declined to acquiesce to Vijuve’s demand that Kaspien purchase over $700,000 of products. In total, Vijuve sought $774,000 in damages. Kaspien denied that it breached the agreement and filed various counterclaims. Kaspien sought at least $229,000 from Vijuve for breach of contract and/or specific performance. On June 26, 2023, the Court granted our motion for summary judgment and dismissed Vijuve’s claim against Kaspien.

Contingent Value Rights
 
On March 30, 2020, the Company entered into the Contingent Value Rights Agreement (the “CVR Agreement”), pursuant to which the Related Party Entities received contingent value rights (“CVRs”) representing the contractual right to receive cash payments from the Company in an amount equal, in the aggregate, to 19.9% of the proceeds (10.35% for Alimco, 1.90% for Kick-Start, and 7.64% for RJHDC) received by the Company in respect of certain intercompany indebtedness owing to it by Kaspien and/or its equity interest in Kaspien. The Company does not anticipate these contingencies being met in Fiscal 2023.

20
On March 2, 2022, the Company entered into a Contingent Value Rights Agreement (the “Second CVR Agreement”) with the Tranche B Lender under the Subordinated Loan Agreement, pursuant to which the Tranche B Lender received contingent value rights (“Second CVRs”) representing the contractual right to receive cash payments from the Company in an amount equal, in the aggregate, to 9.0% of the proceeds received by the Company in respect of certain distributions by the Company or Kaspien; recapitalizations or financings of the Company or Kaspien (with appropriate carve out for trade financing in the ordinary course); repayment of intercompany indebtedness owing to the Company by Kaspien; or sale or transfer of any stock of the Company or Kaspien.

The CVRs terminate upon the earlier to occur of (i) certain consolidations, mergers or similar extraordinary events involving Kaspien (and, if applicable, the making of a cash payment by the Company to the Lenders pursuant to the CVR Agreement in connection therewith) and (ii) March 2, 2032.

21
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
PART 1. FINANCIAL INFORMATION
Item 2 - Management’s Discussion and Analysis of Financial Condition and
Results of Operations
July 29, 2023 and July 30, 2022

Kaspien Holdings Inc., which, together with its consolidated subsidiaries, is referred to herein as “Kaspien”, “the Company”, “we”, “us” and “our”, was incorporated in New York in 1972. We own 100% of the outstanding common stock of Kaspien Inc, through which our principal operations are conducted. Kaspien is a third-party marketplace retailer. The Company leverages in-house expertise, technology, and services to generate revenue through marketplace transactions. Kaspien provides account management, brand development, listings management, data reporting, joint business planning, and comprehensive marketing support services to our vendor partners.  Our target partners are enterprise-level large growth brands that derive margins based on pricing.

We are guided by 5 core principles:
 
•
We are partner obsessed. Our customers are our partners. Every decision is focused on building mutually beneficial relationships that deliver results.
 
•
We are insights driven. We make data actionable. Our curiosity drives us to discover opportunities early and often.
 
•
We create simplicity. We challenge the status quo. We take the complicated and simplify it.
 
•
We take ownership. We make things happen. We hold ourselves accountable and have a bias for action.
 
•
We empower each other. We welcome and learn from diverse experiences. Our empathy ignites innovation and empowers meaningful change.

On June 6, 2023, Kaspien entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which Kaspien sold substantially all of the assets of and certain of the liabilities relating to Kaspien’s agency business model through which Kaspien provides support services for account management, media planning, media analytics, search strategy, business planning, and data reporting to its partners (the “Business” and the transaction, the “Transaction”).  The Transaction closed on June 6, 2023.

The Company’s results have been, and will continue to be, contingent upon management’s ability to understand industry trends and to manage the business in response to those trends and general economic trends. Management monitors several key performance indicators to evaluate its performance, including:

Net Revenue:  The Company measures total year over year sales growth. The Company measures its sales performance through several key performance indicators including number of partners, active product listings and sales per listing.

Cost of Sales and Gross Profit:  Gross profit is calculated based on the cost of product in relation to its retail selling value. Changes in gross profit are impacted primarily by net sales levels, mix of products sold, obsolescence, distribution costs, and Amazon commissions and fulfillment fees.

22
Selling, General and Administrative (“SG&A”) Expenses:  Included in SG&A expenses are payroll and related costs, occupancy charges, general operating and overhead expenses and depreciation charges.

Balance Sheet and Ratios:  The Company views cash and working capital (current assets less current liabilities) as relevant indicators of its financial position.  See Liquidity and Cash Flows section for further discussion of these items.

RESULTS OF OPERATIONS

Thirteen Weeks Ended July 29, 2023
Compared to the Thirteen Weeks Ended July 30, 2022

Net revenue and Gross profit.  The following table sets forth a year-over-year comparison of the Company’s Net revenue and Gross profit:

   
Thirteen Weeks Ended
    
Change
    
Twenty-Six Weeks Ended
    
Change
  
(amounts in
thousands)
  
July 29,
2023
    
July 30,
2022
     $    

%
    
July 29,
2023
    
July 30,
2022
     $    

%
  
                                                     
Net Revenue
  
$
33,136
    
$
33,907
    
$
(771
)
    
-2.3
%
  
$
66,068
    
$
65,697
    
$
371
      
0.6
%
                                                                 
Gross profit
    
7,318
      
6,729
      
589
      
8.8
%
    
14,771
      
13,579
      
1,192
      
8.8
%
% to sales
    
22.1
%
    
19.8
%
                    
22.4
%
    
20.7
%
                

Net Revenue. Net revenue was $33.1 million for the thirteen weeks ended July 29, 2023 a 2.3% decrease from the comparable prior year period. Net revenue was $66.1 million for the twenty-six weeks ended July 29, 2023 a 0.6% increase from the comparable prior year period.

The primary source of revenue is the Retail as a Service (“RaaS”) model, which represented 96.9% of net revenue in the thirteen weeks ended July 29, 2023. The Company generates revenue across a broad array of product lines primarily through the Amazon Marketplace. Categories include apparel, babycare, beauty, health & personal care, home/kitchen/grocery and pet supplies.

Total active partner count as of July 29, 2023 was approximately 89.

   
Thirteen weeks ended
    
Twenty-six weeks ended
  
   
July 29, 2023
    
July 30, 2022
    
Change
    
July 29, 2023
    
July 30, 2022
    
Change
  
Amazon US
  
$
32,119
      
96.9
%
  
$
31,978
      
94.3
%
    
0.4
%
  
$
63,763
      
96.5
%
  
$
61,598
      
93.8
%
    
3.5
%
Amazon International
    
492
      
1.5
%
    
992
      
2.9
%
    
-50.4
%
    
1,026
      
1.6
%
    
2,279
      
3.5
%
    
-55.0
%
Other Marketplaces
    
402
      
1.2
%
    
350
      
1.0
%
    
14.9
%
    
878
      
1.3
%
    
780
      
1.2
%
    
12.6
%
Subtotal Retail as a Service
    
33,013
      
99.6
%
    
33,320
      
98.3
%
    
-0.9
%
    
65,668
      
99.4
%
    
64,657
      
98.4
%
    
1.6
%
Subscriptions
    
123
      
0.4
%
    
587
      
1.7
%
    
-79.0
%
    
400
      
0.6
%
    
1,040
      
1.6
%
    
-61.5
%
Net revenue
  
$
33,136
      
100.0
%
  
$
33,907
      
100.0
%
    
-2.3
%
  
$
66,068
      
100.0
%
  
$
65,697
      
100.0
%
    
0.6
%

On June 6, 2023, Kaspien entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which Kaspien sold substantially all of the assets of and certain of the liabilities relating to Kaspien’s agency business model through which Kaspien provides support services for account management, media planning, media analytics, search strategy, business planning, and data reporting to its partners (the “Business” and the transaction, the “Transaction”).  The Transaction closed on June 6, 2023.

23
Gross Profit. The following table sets forth a period over period comparison of the Company’s gross profit:

 
Thirteen Weeks Ended
    
Change
  
Twenty six Weeks
    
Change
  
(amounts in thousands)
July 29, 2023
 July 30, 2022
     $    

%
  
July 29, 2023
  
 July 30, 2022
     $    

%
  
 
                                                    
Merchandise margin
  
$
13,162
    
$
14,121
    
$
(959
)
    
-6.8
%
  
$
26,621
    
$
28,167
    
$
(1,546
)
    
-5.5
%
% of net revenue
    
39.7
%
    
41.6
%
    
-2.0
%
            
40.3
%
    
42.9
%
    
-2.6
%
        
 
                                                                
Fulfillment fees
    
(3,945
)
    
(4,654
)
    
709
      
-15.2
%
    
(8,057
)
    
(9,222
)
    
1,165
      
-12.6
%
Warehousing and freight
    
(1,899
)
    
(2,738
)
    
839
      
-30.6
%
    
(3,793
)
    
(5,366
)
    
1,573
      
-29.3
%
Gross profit
  
$
7,318
    
$
6,729
    
$
589
      
8.8
%
  
$
14,771
    
$
13,579
    
$
1,192
      
8.8
%
 
                                                                
% of net revenue
    
22.1
%
    
19.8
%
                    
22.4
%
    
20.7
%
                

Gross profit was $7.3 million for the thirteen weeks ended July 29, 2023, as compared to $6.7 million for the comparable prior year period. The increase in gross profit was primarily attributable to a reduction in Warehousing and Freight expenses and Fulfillment fees. Gross profit as a percentage of net revenue was 22.1% as compared to 19.8% for the thirteen weeks ended July 31, 2022. Merchandise margin for the thirteen-week period ending July 29, 2023 was 39.7% as compared to 41.6% for the comparable prior year period.

Gross profit for the twenty-six weeks ended July 29, 2023 was $14.8 million, or 22.4% of net revenue, as compared to $13.6 million, or 20.7% of net revenue for the comparable prior year period as increased net revenue and reduced warehousing and freight expenses were partially offset by lower merchandise margin.

SG&A Expenses.  The following table sets forth a period over period comparison of the Company’s SG&A expenses:

   
Thirteen Weeks Ended
    
Change
    
Twenty-Six Weeks Ended
    
Change
  
(amounts in thousands)
  
July 29,
2023
    
July 30,
2022
     $    
%
    
July 29,
2023
    
July 30,
2022
     $    

%
  
 
                                                    
Selling expenses
  
$
4,472
    
$
4,876
    
$
(404
)
    
-8.3
%
  
$
9,103
    
$
9,477
    
$
(374
)
    
-3.9
%
General and administrative expenses
    
3,779
      
5,325
      
(1,546
)
    
-29.0
%
    
7,858
      
11,242
      
(3,384
)
    
-30.1
%
Total SG&A expenses
  
$
8,251
    
$
10,201
    
$
(1,950
)
    
-19.1
%
  
$
16,961
    
$
20,719
    
$
(3,758
)
    
-18.1
%

                                                               
As a % of total revenue
    
24.9
%
    
30.1
%
                    
25.7
%
    
31.5
%
                

For the thirteen weeks ended July 29, 2023, SG&A expenses were $8.3 million, the same level as the comparable prior year period. Selling expenses decreased $0.4 million for the thirteen weeks ended July 29, 2023. General and administrative expenses decreased $1.5 million for the thirteen weeks ended July 29, 2023.

Consolidated depreciation and amortization expense for the thirteen weeks ended July 29, 2023 was $0.2 million as compared to $0.3 million for the comparable prior year period.

24
For the twenty-six weeks ended July 29, 2023, SG&A expenses were $17.0 million as compared to $20.7 million for the comparable prior year period. Selling expenses decreased $0.4 million for the twenty-six weeks ended July 29, 2023. General and administrative expenses decreased $3.4 million for the twenty-six weeks ended July 30, 2022.

Consolidated depreciation and amortization expense for the twenty-six weeks ended July 30, 2022 was $0.4 million as compared to $0.5 million for the comparable prior year period.

Interest Expense.   Interest expense was $1.0 million for the thirteen weeks ended July 29, 2023 compared to $0.9 million for the thirteen weeks ended July 30, 2022.  The increase in interest expense was due to increased long-term borrowings and higher interest rates on short term borrowings.

Interest expense was $1.8 million for the twenty-six weeks ended July 29, 2023 compared to $1.7 million for the twenty-six weeks ended July 30, 2022.  The increase in interest expense was due to long-term borrowings and higher interest rates on short term borrowings.  See Note 6 to the Condensed Consolidated Financial Statements for further detail on the Company’s debt.

Other Income. Other income for the thirteen and twenty-six week periods ended July 29, 2023 was $0.8 million and represented proceeds from an insurance claim.

Income Tax Expense.   Based on available objective evidence, management concluded that a full valuation allowance should be recorded against the Company's deferred tax assets  As a result, there were insignificant tax expense amounts recorded during the thirteen weeks ended July 29, 2023 and July 30, 2022.
 
Net Loss. The net loss for the thirteen weeks ended July 29, 2023 was $1.2 million as compared to $4.4 million for the comparable prior year period.
 
LIQUIDITY

Liquidity and Cash Flows:
 
The Company’s primary sources of liquidity are its borrowing capacity under its Credit Facility, available cash and cash equivalents, and to a lesser extent, cash generated from operations. Our cash requirements relate primarily to working capital needed to operate Kaspien, including funding operating expenses, the purchase of inventory and capital expenditures. Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; and successful implementation of our strategy and planned activities.

The Company incurred a net loss of $3.3 million and $8.8 million for the twenty-six weeks ended July 29, 2023 and July 30, 2022, respectively.  The decrease in the net loss was primarily attributable to an increase in sales and gross margin and reductions in SG&A expenses. In addition, the Company has an accumulated deficit of $143.3 million as of July 29, 2023 and net cash used in operating activities for the twenty-six weeks ended July 29, 2023 was $0.7 million. Net cash used in operating activities for the twenty-six weeks ended July 30, 2022 was $5.9 million.
 
As disclosed in the Company's Annual Report on Form 10-K filed April 28, 2023, the Company experienced negative cash flows from operations during fiscal 2022 and 2021 and we expect to incur net losses in fiscal 2023.

25
There can be no assurance that we will be successful in further implementing our business strategy or that the strategy, including the completed initiatives, will be successful in sustaining acceptable levels of sales growth and profitability. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

The unaudited condensed consolidated financial statements for the twenty-six weeks ended July 29, 2023 were prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ability of the Company to meet its liabilities and to continue as a going concern is dependent on improved profitability, the strategic initiatives for Kaspien and the availability of future funding. Based on recurring losses from operations, negative cash flows from operations, the expectation of continuing operating losses for the foreseeable future, and uncertainty with respect to any available future funding, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

As of July 29, 2023, we had cash and cash equivalents of $0.3 million, a net working deficit of $0.7 million, and $8.8 million in borrowings on our revolving credit facility, as further discussed below. As of July 29, 2023 and July 30, 2022, the Company had no outstanding letters of credit. The Company had $3.4 million and $7.7 million available for borrowing under the Credit Facility as of July 29, 2023 and July 30, 2022, respectively.

On July 12, 2022, the Company entered into a Securities Purchase Agreement (the “PIPE Purchase Agreement”) with a single institutional investor for a private placement offering (“Private Placement”) of the Company’s common stock (the “Common Stock”) or pre-funded warrants, with each pre-funded warrant exercisable for one share of Common Stock (the “Pre-Funded Warrants”), and warrants exercisable for one share of Common Stock (the “Investor Warrants”). Pursuant to the PIPE Purchase Agreement, the Company has agreed to issue and sell 1,818,182 shares (the “Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof together with Investor Warrants to purchase up to 2,457,160 shares of Common Stock. Each share of Common Stock and accompanying Investor Warrant will be sold together at a combined offering price of $3.30 per share.

The Pre-Funded Warrants are immediately exercisable, at a nominal exercise price of $0.001, and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. As of July 29, 2023 all Pre-Funded Warrants have been exercised.

The Investor Warrants have an exercise price of $3.13 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. The Investor Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

The Private Placement closed on July 14, 2022. The gross proceeds to the Company from the Private Placement, after deducting placement agent fees and other estimated offering expenses payable by the Company, were approximately $7.1 million. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

26
The following table sets forth a summary of key components of cash flow and working capital:
   
As of or for the
Twenty-Six Weeks Ended
     Change  
(amounts in thousands)
  
July 29,
2023
    
July 30,
2022
    

$
 
Operating Cash Flows
  
$
(719
)
  
$
(5,893
)
  
$
5,174
  
Investing Cash Flows(1)
    
(137
)
    
(616
)
    
479
  
Financing Cash Flows
    
(15
)
    
6,026
      
(6,041
)
 
                        
Capital Expenditures(1)
    
(137
)
    
(616
)
    
479
  
 
                        
Cash, Cash Equivalents, and Restricted Cash (2)
    
2,755
      
4,340
      
(1,585
)
Merchandise Inventory
    
26,055
      
26,672
      
(617
)
 
                        
(1) Consists entirely of capital expenditures
                        
 
                        
(2) Cash and cash equivalents per condensed consolidated balance sheets
  
$
282
    
$
1,309
    
$
(1,027
)
Add: restricted cash
    
2,473
      
3,031
      
(558
)
Cash, cash equivalents, and restricted cash
  
$
2,755
    
$
4,340
    
$
(1,585
)

Cash used in operations was $0.7 million for the twenty-six weeks ended July 29, 2023, primarily due to net loss of $3.3 million, a decrease of $0.6 million in accrued expenses, a decrease of $0.6  million in other long-term liabilities, net of a $1.2 million increase in accounts payable.

Cash used by investing activities was $0.1 million  and $0.6 million for the twenty-six weeks periods ended July 29, 2023 and July 30, 2022, which consisted entirely of capital expenditures.

Cash used by financing activities was $15,000 for the twenty-six weeks ended July 29, 2023.

Cash provided by financing activities was $6.0 million for the twenty-six weeks ended July 30, 2022.  The primary source of cash was $5.0 million raised from the issuance of subordinated debt and $7.1 million from the Private Placement offering partially offset by the payment of short-term borrowings of $6.1 million.

Capital Expenditures.  During the thirteen weeks ended July 29, 2023, the Company made capital expenditures of $0.1 million. The Company currently plans to spend approximately $0.5 million for capital expenditures during fiscal 2023.

CRITICAL ACCOUNTING ESTIMATES

The preparation of financial statements and related disclosures in conformity with accounting principles generally accepted in the United States requires that management apply accounting policies and make estimates and assumptions that affect results of operations and the reported amounts of assets and liabilities in the financial statements.  Management continually evaluates its estimates and judgments including those related to merchandise inventory and return costs and income taxes.  Management bases its estimates and judgments on historical experience and other factors that are believed to be reasonable under the circumstances.  Actual results may differ from these estimates under different assumptions or conditions.

27
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations included in the Form 10-K as of and for the year ended January 28, 2023 includes a summary of the critical accounting policies and methods used by the Company in the preparation of its interim condensed consolidated financial statements.  The Company’s significant accounting policies are the same as those described in Note 1 to the Company’s Consolidated Financial Statements on Form 10-K for the fiscal year ended January 28, 2023.

Recent Accounting Pronouncements:

The information set forth under Note 2, Recently Adopted Accounting Pronouncements section contained in Item 1, “Notes to Interim Condensed Consolidated Financial Statements”, is incorporated herein by reference.

28
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
PART I – FINANCIAL INFORMATION

Item 3 – Quantitative and Qualitative Disclosures about Market Risk

Not required under the requirements of a Smaller Reporting Company.

Item 4 – Controls and Procedures

 (a)    Evaluation of disclosure controls and procedures.    The Company’s Principal  Executive Officer and Chief Financial Officer, after evaluating the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) and 15d-15(e)) as of July 29, 2023, have concluded that as of such date the Company’s disclosure controls and procedures were not effective and designed to ensure that (i) information required to be disclosed by the issuer in the reports that it files or submits under the Securities Exchange Act of 1934 (the “Exchange Act”) is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and (ii) information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

(b)    Changes in internal controls.     There have been no changes in the Company’s internal controls over financial reporting that occurred during the fiscal quarter covered by this quarterly report that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.

29
KASPIEN HOLDINGS INC. AND SUBSIDIARIES
 
PART II - OTHER INFORMATION

Item 1 – Legal Proceedings

The Company is subject to legal proceedings and claims that have arisen in the ordinary course of its business and have not been finally adjudicated.  Although there can be no assurance as to the ultimate disposition of these matters, it is management’s opinion, based upon the information available at this time, that the expected outcome of these matters, individually and in the aggregate, will not have a material adverse effect on the results of operations and financial condition of the Company. As a result, the liability for the cases listed below is remote.

Retailer Agreement Dispute

On June 18, 2021, Vijuve Inc. filed a lawsuit against Kaspien Inc. in the United States District Court for the Eastern District of Washington (Case No. 2:21-cv-00192-SAB) concerning a Retailer Agreement that the parties entered into in September of 2020. Vijuve manufactures skin care products and face massagers. The parties agreed that Kaspien would sell Vijuve’s products on Amazon. The complaint alleged that Kaspien breached the Retailer Agreement when it declined to acquiesce to Vijuve’s demand that Kaspien purchase over $700,000 of products. In total, Vijuve sought $774,000 in damages. Kaspien denied that it breached the agreement and filed various counterclaims. Kaspien sought at least $229,000 from Vijuve for breach of contract and/or specific performance. On June 26, 2023, the Court granted our motion for summary judgment and dismissed Vijuve’s claim against Kaspien.

Item 1A – Risk Factors

Risks relating to the Company’s business and Common Stock are described in detail in Item 1A of the Company’s most recently filed Annual Report on Form 10-K for the fiscal year ended January 28, 2023.

Item 2 – Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3 – Defaults Upon Senior Securities

None.

Item 4 – Mine Safety Disclosure

Not Applicable.

Item 5 – Other Information

(c) Insider Trading Arrangements

During the quarter ended July 31, 2023, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended), adopted or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (each as defined in Item 408(a) and (c), respectively, of Regulation S-K).

30
Item 6 – Exhibits

(A) Exhibits -

Exhibit No.
Description
4.1
Asset Purchase Agreement dated as of June 6, 2023 by and among Kaspien Inc.  and Channel Key LLC. (Incorporated by reference to Exhibit 2.1 to Form 8-K Filed June 6, 2023)*
   
Chief Executive Officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
Chief Financial Officer certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
   
Certification pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
   
101.INS
XBRL Instance Document (furnished herewith)
   
101.SCH
XBRL Taxonomy Extension Schema (furnished herewith)
   
101.CAL
XBRL Taxonomy Extension Calculation Linkbase (furnished herewith)
   
101.DEF
XBRL Taxonomy Extension Definition Linkbase (furnished herewith)
   
101.LAB
XBRL Taxonomy Extension Label Linkbase (furnished herewith)
   
101.PRE
XBRL Taxonomy Extension Presentation Linkbase (furnished herewith)
   
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).

* Schedules, annexes and exhibits attached to the Asset Purchase Agreement have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Kaspien Holdings Inc. will furnish the omitted items to the Securities Exchange Commission upon request by the Commission.
31
SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

KASPIEN HOLDINGS INC.

September 12, 2023
By: /s/ Brock Kowalchuk
 
Brock Kowalchuk
 
Principal Executive Officer
 
(Principal Executive Officer)
   
September 12, 2023
By: /s/ Edwin Sapienza
 
Edwin Sapienza
 
Chief Financial Officer
 
(Principal and Chief Accounting Officer)


32
Exhibit 31.1

CHIEF EXECUTIVE OFFICER CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES OXLEY ACT 2002

I, Brock Kowalchuk certify that:


 (1)
I have reviewed this report on Form 10–Q of the Registrant;


(2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


(3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


(4)
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


(5)
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated:   September 12, 2023
 /s/ Brock Kowalchuk
 
Brock Kowalchuk
 
Principal Executive Officer
 
Kaspien Holdings Inc.


Exhibit 31.2

CHIEF FINANCIAL OFFICER CERTIFICATION PURSUANT TO SECTION 302 OF SARBANES OXLEY ACT 2002

I, Edwin Sapienza, Chief Financial Officer of Kaspien Holdings Inc. (the “Registrant”), certify that:


 (1)
I have reviewed this report on Form 10–Q of the Registrant;


(2)
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;


(3)
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;


(4)
The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:


a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b.
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c.
Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d.
Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and


(5)
The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):


a.
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and


b.
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Dated:   September 12, 2023
 /s/ Edwin Sapienza
 
Edwin Sapienza
 
Chief Financial Officer
 
Kaspien Holdings Inc.
 

Exhibit 32

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Kaspien Holdings Inc. (the “Company”) on Form 10-Q for the period ending July 29, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Brock Kowalchuk, Principal Executive Officer of the Company and Edwin Sapienza, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of our knowledge:


 (1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and


(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Brock Kowalchuk
/s/ Edwin Sapienza
  
Brock Kowalchuk
Edwin Sapienza
Principal Executive Officer
Chief Financial Officer
September 12, 2023
September 12, 2023


v3.23.2
Document and Entity Information - shares
 6 Months Ended
Jul. 29, 2023
Sep. 10, 2023
Cover [Abstract]    
Document Type 10-Q  
Amendment Flag false  
Document Quarterly Report true  
Document Period End Date Jul. 29, 2023  
Current Fiscal Year End Date --01-27  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Document Transition Report false  
Entity File Number 0-14818  
Entity Registrant Name KASPIEN HOLDINGS INC.  
Entity Central Index Key 0000795212  
Entity Incorporation, State or Country Code NY  
Entity Tax Identification Number 14-1541629  
Entity Address, Address Line One 2818 N. Sullivan Rd.  
Entity Address, Address Line Two Ste 130  
Entity Address, City or Town Spokane Valley  
Entity Address, State or Province WA  
Entity Address, Postal Zip Code 99216  
City Area Code 509  
Local Phone Number 900-6287  
Title of 12(b) Security Common Stock, $.01 par value per share  
Trading Symbol KSPN  
Security Exchange Name NONE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   4,969,738
v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Jul. 29, 2023
Jan. 28, 2023
Jul. 30, 2022
CURRENT ASSETS      
Cash and cash equivalents $ 282 $ 1,130 $ 1,309
Restricted cash 1,158 1,158 1,158
Accounts receivable 2,211 1,969 2,082
Merchandise inventory 26,055 26,704 29,363
Prepaid expenses and other current assets 620 999 618
Total current assets 30,326 31,960 34,530
Restricted cash 1,315 1,338 1,873
Fixed assets, net 1,769 1,999 2,357
Operating lease right-of-use assets 1,181 1,505 1,823
Cash Surrender Value 3,652 3,371 3,768
Other assets 566 566 777
TOTAL ASSETS 38,809 40,739 45,128
CURRENT LIABILITIES      
Accounts payable 8,196 7,044 8,012
Short-term borrowings 8,797 8,812 3,855
Short-term debt 11,082 0 0
Accrued expenses and other current liabilities 2,291 2,876 1,753
Current portion of operating lease liabilities 689 695 550
Total current liabilities 31,055 19,427 14,170
Operating lease liabilities 727 1,019 1,416
Long-term debt 0 9,790 8,548
Other long-term liabilities 11,308 11,604 13,788
TOTAL LIABILITIES 43,090 41,840 37,922
SHAREHOLDERS' EQUITY (DEFICIT)      
Preferred stock ($0.01 par value; 5,000,000 shares authorized; none issued) 0 0 0
Common stock ($0.01 par value; 200,000,000 shares authorized; 5,432,072, 5,432,072 and 3,911,985 shares issued, respectively) 54 54 39
Additional paid-in capital 214,161 214,029 263,723
Treasury stock at cost (467,069, 467,069 and 1,410,378 shares, respectively) (76,132) (76,132) (125,906)
Accumulated other comprehensive loss 886 886 (910)
Accumulated deficit (143,250) (139,938) (129,740)
TOTAL SHAREHOLDERS' EQUITY (DEFICIT) (4,281) (1,101) 7,206
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) $ 38,809 $ 40,739 $ 45,128
v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares
Jul. 29, 2023
Jan. 28, 2023
Jul. 30, 2022
SHAREHOLDERS' EQUITY (DEFICIT)      
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 200,000,000 200,000,000 200,000,000
Common stock, shares issued (in shares) 5,432,072 5,432,072 3,911,985
Treasury stock (in shares) 467,069 467,069 1,410,378
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jul. 29, 2023
Jul. 30, 2022
Jul. 29, 2023
Jul. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]        
Net revenue $ 33,136 $ 33,907 $ 66,068 $ 65,697
Cost of sales 25,818 27,178 51,297 52,118
Gross profit 7,318 6,729 14,771 13,579
Selling, general and administrative expenses 8,251 10,201 16,961 20,719
Loss from operations (933) (3,472) (2,190) (7,140)
Interest expense 954 901 1,848 1,663
Other income (777) 0 (777) 0
Loss before income tax expense (1,110) (4,373) (3,261) (8,803)
Income tax expense 51 43 51 43
Net loss $ (1,161) $ (4,416) $ (3,312) $ (8,846)
BASIC AND DILUTED LOSS PER SHARE:        
Basic loss per common share (in dollars per share) $ (0.23) $ (1.69) $ (0.67) $ (3.47)
Diluted loss per common share (in dollars per share) $ (0.23) $ (1.69) $ (0.67) $ (3.47)
Weighted average number of common shares outstanding - basic (in shares) 4,965 2,613 4,965 2,553
Weighted average number of common shares outstanding - diluted (in shares) 4,965 2,613 4,965 2,553
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jul. 29, 2023
Jul. 30, 2022
Jul. 29, 2023
Jul. 30, 2022
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS [Abstract]        
Net loss $ (1,161) $ (4,416) $ (3,312) $ (8,846)
Amortization of pension gain 0 0 0 0
Comprehensive loss $ (1,161) $ (4,416) $ (3,312) $ (8,846)
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
shares in Thousands, $ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Treasury Stock At Cost [Member]
Accumulated Other Comprehensive Loss [Member]
Retained Earnings (Accumulated Deficit) [Member]
Total
Balance at Jan. 29, 2022 $ 39 $ 359,220 $ (230,170) $ (910) $ (120,894) $ 7,285
Balance (in shares) at Jan. 29, 2022 3,903   (1,410)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss $ 0 0 $ 0 0 (8,846) (8,846)
Issuance of shares, net of expenses (in shares) 0   638      
Issuance of shares, net of expenses $ 0 (97,127) $ 104,264 0 0 7,137
Issuance of warrants $ 0 1,518 $ 0 0 0 1,518
Common stock issued- Director grants (in shares) 9   0      
Common stock issued- Director grants $ 0 41 $ 0 0 0 41
Amortization of unearned compensation/restricted stock amortization 0 71 0 0 0 71
Balance at Jul. 30, 2022 $ 39 263,723 $ (125,906) (910) (129,740) 7,206
Balance (in shares) at Jul. 30, 2022 3,912   (772)      
Balance at Apr. 30, 2022 $ 39 360,738 $ (230,170) (910) (125,324) 4,375
Balance (in shares) at Apr. 30, 2022 3,903   (1,410)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss $ 0 0 $ 0 0 (4,416) (4,416)
Issuance of shares, net of expenses (in shares) 0   638      
Issuance of shares, net of expenses $ 0 (97,127) $ 104,264 0 0 7,137
Common stock issued- Director grants (in shares) 9   0      
Common stock issued- Director grants $ 0 41 $ 0 0 0 41
Amortization of unearned compensation/restricted stock amortization 0 71 0 0 0 71
Balance at Jul. 30, 2022 $ 39 263,723 $ (125,906) (910) (129,740) 7,206
Balance (in shares) at Jul. 30, 2022 3,912   (772)      
Balance at Jan. 28, 2023 $ 54 214,029 $ (76,132) 886 (139,938) (1,101)
Balance (in shares) at Jan. 28, 2023 5,432   (467)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss $ 0 0 $ 0 0 (3,312) (3,312)
Amortization of unearned compensation/restricted stock amortization 0 132 0 0 0 132
Balance at Jul. 29, 2023 $ 54 214,161 $ (76,132) 886 (143,250) (4,281)
Balance (in shares) at Jul. 29, 2023 5,432   (467)      
Balance at Apr. 29, 2023 $ 54 214,092 $ (76,132) 886 (142,089) (3,189)
Balance (in shares) at Apr. 29, 2023 5,432   (467)      
Increase (Decrease) in Stockholders' Equity [Roll Forward]            
Net loss $ 0 0 $ 0 0 (1,161) (1,161)
Amortization of unearned compensation/restricted stock amortization 0 69 0 0 0 69
Balance at Jul. 29, 2023 $ 54 $ 214,161 $ (76,132) $ 886 $ (143,250) $ (4,281)
Balance (in shares) at Jul. 29, 2023 5,432   (467)      
v3.23.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 6 Months Ended
Jul. 29, 2023
Jul. 30, 2022
OPERATING ACTIVITIES:    
Net Loss $ (3,312) $ (8,846)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation of fixed assets 366 594
Amortization of intangible assets 0 0
Stock-based compensation 133 112
Amortization of ROU asset 325 321
Amortization of warrant interest 524 612
Interest on long term debt 768 389
Change in cash surrender value (281) 386
Changes in operating assets and liabilities that provide (use) cash:    
Accounts receivable (242) 253
Merchandise inventory 649 (86)
Prepaid expenses and other current assets 379 32
Other long-term assets 0 188
Accounts payable 1,152 1,740
Accrued expenses and other current liabilities (591) (999)
Other long-term liabilities (589) (589)
Net cash used in operating activities (719) (5,893)
INVESTING ACTIVITIES:    
Purchases of fixed assets (137) (616)
Net cash provided by (used in) investing activities (137) (616)
FINANCING ACTIVITIES:    
Payments of short term borrowings (15) (6,111)
Proceeds from long term borrowings 0 5,000
Proceeds from issuance of shares, net of expense 0 7,137
Net cash provided by (used in) financing activities (15) 6,026
Net increase (decrease) in cash, cash equivalents, and restricted cash (871) (483)
Cash, cash equivalents, and restricted cash, beginning of period 3,626 4,823
Cash, cash equivalents, and restricted cash, end of period 2,755 4,340
Supplemental disclosures and non-cash investing and financing activities:    
Interest paid 543 386
Warrants issued with debt $ 0 $ 1,633
v3.23.2
Nature of Operations
 6 Months Ended
Jul. 29, 2023
Nature of Operations [Abstract]  
Nature of Operations
Note 1. Nature of Operations
Kaspien Holdings Inc., which, together with its consolidated subsidiaries, is referred to herein as “Kaspien”, “the Company”, “we”, “us” and “our”, was incorporated in New York in 1972. We own 100% of the outstanding common stock of Kaspien Inc, through which our principal operations are conducted. Kaspien is a third-party marketplace retailer. The Company leverages in-house expertise, technology, and services to generate revenue through marketplace transactions. Kaspien provides account management, brand development, listings management, data reporting, joint business planning, and comprehensive marketing support services to our vendor partners.  Our target partners are enterprise-level large growth brands that derive margins based on pricing.

We are guided by 5 core principles:
•
We are partner obsessed. Our customers are our partners. Every decision is focused on building mutually beneficial relationships that deliver results.

•
We are insights driven. We make data actionable. Our curiosity drives us to discover opportunities early and often.

•
We create simplicity. We challenge the status quo. We take the complicated and simplify it.

•
We take ownership. We make things happen. We hold ourselves accountable and have a bias for action.

•
We empower each other. We welcome and learn from diverse experiences. Our empathy ignites innovation and empowers meaningful change.

On June 6, 2023, Kaspien entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which Kaspien sold substantially all of the assets of and certain of the liabilities relating to Kaspien’s agency business model through which Kaspien provides support services for account management, media planning, media analytics, search strategy, business planning, and data reporting to its partners (the “Business” and the transaction, the “Transaction”). The Transaction closed on June 6, 2023.
Liquidity and Cash Flows:
The Company’s primary sources of liquidity are its borrowing capacity under its Credit Facility, available cash and cash equivalents, and to a lesser extent, cash generated from operations. Our cash requirements relate primarily to working capital needed to operate Kaspien, including funding operating expenses, the purchase of inventory and capital expenditures.
 
The Company incurred a net loss of $3.3 million and $8.8 million for the twenty-six weeks ended July 29, 2023 and July 30, 2022, respectively.  The decrease in the net loss was primarily attributable to a decrease in sales and gross margin. In addition, the Company has an accumulated deficit of $143.3 million as of July 29, 2023 and net cash used in operating activities for the twenty-six weeks ended July 29, 2023 was $0.7 million. Net cash used in operating activities for the twenty-six weeks ended July 30, 2022 was $5.9 million.

As disclosed in the Company’s Annual Report on Form 10-K filed April 28, 2023, the Company experienced negative cash flows from operations during fiscal 2022 and 2021 and we expect to incur net losses in fiscal 2023.

Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; and successful implementation of our strategy and planned activities. There can be no assurance that we will be successful in further implementing our business strategy or that the strategy, including the completed initiatives, will be successful in sustaining acceptable levels of sales growth and profitability. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
The unaudited condensed consolidated financial statements for the twenty-six weeks ended July 29, 2023 were prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ability of the Company to meet its liabilities and to continue as a going concern is dependent on improved profitability, the strategic initiatives for Kaspien and the availability of future funding. Based on recurring losses from operations, negative cash flows from operations, the expectation of continuing operating losses for the foreseeable future, and uncertainty with respect to any available future funding, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
As of July 29, 2023, we had cash and cash equivalents of $0.3 million, a net working deficit of $0.7 million, and $8.8 in borrowings on our revolving credit facility, as further discussed below.
As of January 28, 2023, the Company had borrowings of $8.8 million under the Credit Facility. As of April 29, 2023 and April 30, 2022, the Company had no outstanding letters of credit. The Company had $3.4 million and $7.7 million available for borrowing under the Credit Facility as of  July 29, 2023 and July 30, 2022, respectively.
Credit Facility
On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

On March 30, 2020, the Company and Kaspien Inc. (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.


On April 7, 2021, the Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the Credit Facility was extended to February 20, 2024, and the early termination fees were accordingly reset; (ii) the LIBOR floor was reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.


On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (the “Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).



On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the loan agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of July 29, 2023 and July 30, 2022, the Company had borrowings of $8.8 and $3.9 million under the Credit Facility, respectively.

Subordinated Debt Agreement
On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien with a scheduled maturity date of May 22, 2023. As of July 29, 2023, unamortized debt issuance costs of $0.1 million are included in “Long Term Debt” on the unaudited condensed consolidated balance sheet.
Directors Jonathan Marcus, Thomas Simpson, and Michael Reickert are the chief executive officer of Alimco Re Ltd. (“Alimco”), the managing member of Kick-Start III, LLC and Kick-Start IV, LLC (“Kick-Start”), and a trustee of the Robert J. Higgins TWMC Trust (the “Trust”), an affiliate of RJHDC, LLC (“RJHDC” and together with Alimco and Kick-Start, “Related Party Entities”), respectively.  The Related Party Entities are parties to the Subordinated Loan Agreement.


Amendment No. 2 to Subordinated Loan and Security Agreement



On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) with the “Lenders and the Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.


The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.



Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.


The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.


The Loan Parties paid certain customary fees and expenses in connection with the Additional Subordinated Loan and Amendment No. 2.


In addition to the aforementioned current sources of existing working capital, the Company may explore certain other strategic alternatives that may become available to the Company, as well continuing our efforts to generate additional sales and increase margins. However, at this time the Company has no commitments to obtain any additional funds, and there can be no assurance such funds will be available on acceptable terms or at all, should we require such additional funds. If the Company is unable to improve its operations, it may be required to obtain additional funding, and the Company’s financial condition and results of operations may be materially adversely affected.
Furthermore, broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance, and may adversely impact our ability to raise additional funds, should we require such additional funds.
v3.23.2
Basis of Presentation
 6 Months Ended
Jul. 29, 2023
Basis of Presentation [Abstract]  
Basis of Presentation
Note 2. Basis of Presentation
The accompanying interim condensed consolidated financial statements consist of Kaspien Holdings Inc., its wholly owned subsidiaries, Kaspien NY, LLC (f/k/a Trans World NY Sub, Inc. (f/k/a Record Town, Inc.)) and its subsidiaries, and Kaspien, Inc. All intercompany accounts and transactions have been eliminated.
The interim condensed consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited interim condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of net revenue and expenses during the reporting period. Actual results could differ from those estimates. Certain information and footnote disclosures normally included in the financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to rules and regulations applicable to interim financial statements.

The accompanying unaudited interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto and Management’s Discussion and Analysis of Financial Condition and Results of Operations as of and for the year ended January 28, 2023 contained in the Company’s Annual Report on Form 10-K filed April 28, 2023.  The results of operations for the thirteen weeks ended July 29, 2023 are not necessarily indicative of the results to be expected for the entire fiscal year ending February 3, 2024.

The Company’s significant accounting policies are the same as those described in Note 1 to the Company’s Consolidated Financial Statements on Form 10-K for the fiscal year ended January 28, 2023.
v3.23.2
Recently Adopted Accounting Pronouncements
 6 Months Ended
Jul. 29, 2023
Recently Adopted Accounting Pronouncements [Abstract]  
Recently Adopted Accounting Pronouncements
Note 3. Recently Adopted Accounting Pronouncements
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost. The model replaces the probable, incurred loss model for those assets and instead, broadens the information an entity must consider in developing its expected credit loss estimate for assets measured at amortized cost. This standard will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022. We have completed our evaluation and have determined that the update will not have a material impact on our consolidated financial condition, results of operations, or cash flows.

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 provides, among other things, guidance that modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate; modifications of contracts within the scope of Topic 840, Leases, should be accounted for as a continuation of the existing contract; and, changes in the critical terms of hedging relationships, caused by reference rate reform, should not result in the de-designation of the instrument, provided certain criteria are met. The Company’s exposure to LIBOR rates includes its credit facility. The amendments are effective as of March 12, 2020 through December 31, 2022. We have completed our evaluation and have determined that the update will not have a material impact on our consolidated financial condition, results of operations, or cash flows.

Recent accounting pronouncements pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.
v3.23.2
Depreciation and Amortization
 6 Months Ended
Jul. 29, 2023
Depreciation and Amortization [Abstract]  
Depreciation and Amortization
Note 4. Depreciation and Amortization
Depreciation and amortization included in selling, general and administrative expenses of the interim condensed consolidated statements of operations for the thirteen weeks ended July 29, 2023 and July 30, 2022 was $0.2 million and $0.3 million, respectively.

Depreciation and amortization included in selling, general and administrative expenses of the interim condensed consolidated statements of operations for the twenty-six weeks ended July 29, 2023 and July 30, 2022 was $0.4 million and $0.6 million, respectively.
v3.23.2
Restricted Cash
 6 Months Ended
Jul. 29, 2023
Restricted Cash [Abstract]  
Restricted Cash
Note 5. Restricted Cash
As a result of the death of its former Chairman, the Company holds $2.5 million in a rabbi trust, of which $1.2 million is classified as restricted cash in current assets and $1.3 million is classified as restricted cash in other assets on the accompanying interim condensed consolidated balance sheet as of July 29, 2023.
A summary of cash, cash equivalents and restricted cash is as follows (amounts in thousands):

   
July 29,
    
January 28,
    
July 30,
  
     2023     2023     2022
 
Cash and cash equivalents
  
$
282
    
$
1,130
    
$
1,309
  
Restricted cash
    
2,473
      
2,496
      
3,031
  
Total cash, cash equivalents and restricted cash
  
$
2,755
    
$
3,626
    
$
4,340
  
v3.23.2
Debt
 6 Months Ended
Jul. 29, 2023
Debt [Abstract]  
Debt
Note 6.  Debt
Credit Facility
On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).
The commitments by the lenders under the Credit Facility are subject to borrowing base and availability restrictions. Up to $5.0 million of the Credit Facility may be used for the making of swing line loans.
Interest under the Credit Facility accrues, subject to certain terms and conditions under the Loan Agreement, at a SOFR Rate or Base Rate, plus, in each case, an Applicable Margin, which is determined by reference to the level of Availability as defined in the Loan Agreement, with the Applicable Margin for SOFR Rate loans ranging from 4.00% to 4.50% and the Applicable Margin for Base Rate loans ranging from 3.00% to 3.50%.
The Credit Facility is secured by a first priority security interest in substantially all of the assets of Kaspien, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Credit Facility (collectively, the “Credit Facility Parties”) and by a first priority pledge by the Company of its equity interests in Kaspien. The Company will provide a limited guarantee of Kaspien’s obligations under the Credit Facility.
Among other things, the Loan Agreement limits Kaspien’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets. The Loan Agreement also requires Kaspien to comply with a financial maintenance covenant.
The Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the Credit Facility Parties taken as a whole, the occurrence of an uninsured loss to a material portion of collateral and failure of the obligations under the Credit Facility to constitute senior indebtedness under any applicable subordination or intercreditor agreements.

On March 30, 2020, the Company and Kaspien (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan

Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.
 
On April 7, 2021, Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the Credit Facility was extended to February 20, 2024, and the early termination fees were accordingly reset; (ii) the LIBOR floor was reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.

On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (“Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).

On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the Loan Agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of July 29, 2023, the Company had borrowings of $8.8 million under the Credit Facility. The Company had borrowings of $3.9 million as of July 30, 2022. As of July 29, 2023, unamortized debt issuance costs of $0.1 million related to the Credit Facility are included in Other assets on the unaudited condensed consolidated balance sheet.
The Company records short term borrowings at cost, in which the carrying value approximates fair value due to its short-term maturity.
Subordinated Loan Agreement

On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien. On September 17, 2021, the Loan Parties entered into Amendment No. 1 to the Subordinated Loan Agreement which extended the maturity of the loan to March 31, 2024. As of October 29, 2022, unamortized debt issuance costs of $0.1 million are included in “Long-Term Debt” on the consolidated balance sheet.
Interest on the Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of twelve percent (12.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Subordinated Loan.

The Subordinated Loan is secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement (collectively, the “Second Lien Credit Facility Parties”). The Company will provide a limited guarantee of Kaspien ’s obligations under the Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.
 
The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the Second Lien Credit Facility Parties taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.
 
In conjunction with the Subordinated Debt Agreement, the Company issued warrants to purchase up to 244,532 shares of Common Stock to the Related Party Entities (127,208 shares for Alimco, 23,401 shares for Kick-Start, and 93,923 shares for RJHDC), subject to adjustment in accordance with the terms of the Warrants, at an exercise price of $0.01 per share. As of July 29, 2023, 5,126 warrants remain outstanding.

The value of the warrants of $0.8 million was allocated against the principal proceeds of the Subordinated Debt Agreement, $0.1 million of which was unamortized as of July 29, 2023.

On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) the “Lenders and Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.

The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.

Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.

The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.

In conjunction with the Subordinated Debt Agreement, the Company issued warrants to purchase up to warrants to purchase up to 320,000 shares of common stock of the Company (subject to adjustment in accordance with the terms of the Warrants, the “Warrant Shares”) at an exercise price of $0.01 per share.  The Warrants are exercisable during the period commencing on March 2, 2022 and ending on the earlier of (a) 5:00 p.m. Eastern Standard Time on the five (5)-year anniversary thereof, or if such day is not a business day on the next succeeding business day, or (b) the occurrence of certain consolidations, mergers or similar extraordinary events involving the Company. As of October 29, 2022, all of the warrants remain outstanding.
 
The value of the warrants of $1.6 million was allocated against the principal proceeds of the Subordinated Debt Agreement, of which $0.6 million was unamortized as of July 29, 2023. The value of the warrants was recognized as a discount based on the relative fair value of the consideration received, as an offset to APIC, which will be amortized over the life of the loan.
v3.23.2
Stock Based Compensation
 6 Months Ended
Jul. 29, 2023
Stock Based Compensation [Abstract]  
Stock Based Compensation
Note 7. Stock Based Compensation

The Company has outstanding awards under four employee stock award plans: the 2005 Long Term Incentive and Share Award Plan; the Amended and Restated 2005 Long Term Incentive and Share Award Plan; the 2005 Long Term Incentive and Share Award Plan (as amended and restated April 5, 2017 (the “Old Plans”); and Kaspien Holdings Inc. 2005 Long Term Incentive and Share Award Plan (as amended and restated on August 2, 2022) (the “New Plan”). Collectively, these plans are referred to herein as the Stock Award Plans. The Company no longer issues stock options under the Old Plans.

Equity awards authorized for issuance under the New Plan total 500,000.  As of July 29, 2023, of the awards authorized for issuance under the Stock Award Plans, approximately 195,005 were granted and are outstanding, 35,042 of which were vested and exercisable. Shares available for future grants of options and other share-based awards under the New Plan as of January 28, 2023 were 391,137.
The following table summarizes stock award activity during the thirteen weeks ended July 29, 2023:

    Employee Stock Award Plans
 
   
Number of
Shares
Subject To
Option
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
Term
   
Other
Share
Awards (1)
    
Weighted
Average
Grant Fair
Value
 
Balance January 28, 2023
    
123,642
    
$
6.00
      
7.5
       19,500
     $ 18.35  
Granted
    
-
      
-
      
-
       60,000       0.61  
Forfeited
    
(7,637
)
    
(9.01
)
    
-
       -       -  
Canceled
    
(500
)
    
(97.40
)
    
-
       -       -  
Exercised
    
-
      
-
      
-
       -       -  
Balance July 29, 2023
    
115,505
    
$
5.79
      
8.4
       79,500     $ 4.96  
Exercisable July 29, 2023
    
35,042
    
$
13.37
      
7.0
       -       -  

 (1) Other Share Awards include deferred shares granted to executives and directors.

As of July 29, 2023, the intrinsic value of stock awards outstanding and stock awards exercisable was $0.
v3.23.2
Shareholders' Equity (Deficit)
 6 Months Ended
Jul. 29, 2023
Shareholders' Equity [Abstract]  
Shareholders' Equity
Note 8. Shareholders’ Equity (Deficit)

On July 12, 2022, the Company entered into a Securities Purchase Agreement (the “PIPE Purchase Agreement”) with a single institutional investor for a private placement offering (“Private Placement”) of the Company’s common stock (the “Common Stock”) or pre-funded warrants, with each pre-funded warrant exercisable for one share of Common Stock (the “Pre-Funded Warrants”), and warrants exercisable for one share of Common Stock (the “Investor Warrants”). Pursuant to the PIPE Purchase Agreement, the Company has agreed to issue and sell 1,818,182 shares (the “Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof together with Investor Warrants to purchase up to 2,457,160 shares of Common Stock. Each share of Common Stock and accompanying Investor Warrant will be sold together at a combined offering price of $3.30 per share.

As of July 29, 2023 all of the Prefunded Warrants were exercised in full.

The Investor Warrants have an exercise price of $3.13 per share (subject to adjustment as set forth in the warrant), are exercisable upon issuance and will expire five years from the date of issuance. The Investor Warrants contain standard adjustments to the exercise price including for stock splits, stock dividend, rights offerings and pro rata distributions.

The Private Placement closed on July 14, 2022. The Company received approximately $6 million in gross proceeds from the Private Placement, before deducting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

On July 12, 2022, the Company also entered into a Securities Purchase Agreement (the “Registered Purchase Agreement”) with a single institutional investor, pursuant to which the Company agreed to issue and sell 638,978 shares (the “Registered Shares”) of its Common Stock or Pre-Funded Warrants in lieu thereof, with each Pre-Funded Warrant exercisable for one share of Common Stock (the “Offering”). The Company received approximately $2 million in gross proceeds from the Offering, before deducting discounts and commissions and estimated offering expenses. The Company intends to use the net proceeds from the private placement for working capital and other general corporate purposes.

Net proceeds from the Private Placement and the Offering, after deducting placement agent fees and other estimated offering expenses payable by the Company of $0.9 million, were approximately $7.1 million.

The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, as of April 29, 2023:

Exercise
    
Number
  
Price
    
Outstanding
  
$
0.01
      
325,126
  
$
3.13
      
2,457,160
  
         
2,782,286
  

There were no warrant transactions during the quarter and the weighted average exercise price for the outstanding warrants is $2.77. As of July 29, 2023, the intrinsic value of the warrants was $60,000 with a weighted average remaining term of 4 years.
v3.23.2
Accumulated Other Comprehensive Loss
 6 Months Ended
Jul. 29, 2023
Accumulated Other Comprehensive Loss [Abstract]  
Accumulated Other Comprehensive Loss
Note 9. Accumulated Other Comprehensive Loss
Accumulated other comprehensive loss that the Company reports in the interim condensed consolidated balance sheets represents net loss, adjusted for the difference between the accrued pension liability and accrued benefit cost, net of taxes, associated with the Company’s defined benefit plan. Comprehensive loss consists of net loss for all periods presented.
v3.23.2
Defined Benefit Plan
 6 Months Ended
Jul. 29, 2023
Defined Benefit Plan [Abstract]  
Defined Benefit Plan

Note 10. Defined Benefit Plan



The Company maintains a non-qualified Supplemental Executive Retirement Plan (“SERP”) for certain executive officers of the Company.  The SERP provides eligible executives defined pension benefits that supplement benefits under other retirement arrangements.  As of February 28, 2020, no active employees were participants in the SERP. During the thirteen weeks ended July 29, 2023, the Company did not make any cash contributions to the SERP and presently expects to pay approximately $1.2 million in benefits relating to the SERP during fiscal 2023.

The measurement date for the SERP is the fiscal year end, using actuarial techniques which reflect estimates for mortality, turnover and expected retirement. In addition, management makes assumptions concerning future salary increases. Discount rates are generally established as of the measurement date using theoretical bond models that select high-grade corporate bonds with maturities or coupons that correlate to the expected payouts of the applicable liabilities.

 

The following represents the components of the net periodic pension cost related to the Company’s SERP for the respective periods:


   
Thirteen Weeks Ended
    
Twenty-six Weeks Ended
  
(amounts in thousands)
 
July 29,
    
July 30,
    
July 29,
    
July 30,

  2023
     2022
     2023
     2022
  
                         
Interest cost
  
$
139
    
$
89
    
$
278
    
$
178
  
Net periodic pension cost
  
$
139
    
$
89
    
$
278
    
$
178
  
v3.23.2
Basic and Diluted Loss Per Share
 6 Months Ended
Jul. 29, 2023
Basic and Diluted Loss Per Share [Abstract]  
Basic and Diluted Loss Per Share
Note 11. Basic and Diluted Loss Per Share
Basic loss per share is calculated by dividing net loss by the weighted average common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock (net of any assumed repurchases) that then shared in the earnings of the Company, if any.  It is computed by dividing net loss by the sum of the weighted average shares outstanding and additional common shares that would have been outstanding if the dilutive potential common shares had been issued for the Company’s common stock awards from the Company’s Stock Award Plans.

For the thirteen-week and twenty-six week periods ended July 29, 2023 and July 30, 2022, the impact of all outstanding stock awards was not considered because the Company reported net losses in those periods and such impact would be anti-dilutive.  Accordingly, basic and diluted loss per share was the same.  Total anti-dilutive stock awards for the thirteen and twenty-six weeks ended July 29, 2023 and thirteen and twenty-six weeks ended July 29, 2023 were approximately 0.1 million shares for all periods.

Total anti-dilutive warrants for the thirteen weeks and twenty-six week periods ended July 29, 2023 were approximately 2.8 million shares for both periods.
v3.23.2
Income Taxes
 6 Months Ended
Jul. 29, 2023
Income Taxes [Abstract]  
Income Taxes
Note 12. Income Taxes
In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized.  The ultimate realization of deferred tax assets is dependent on the generation of future taxable income. Management considers the scheduled reversal of taxable temporary differences, projected future taxable income and tax planning strategies in making this assessment.  Based on available objective evidence, management concluded that a full valuation allowance should continue to be recorded against the Company’s deferred tax assets. Management will continue to assess the need for and amount of the valuation allowance against the deferred tax assets by considering all available evidence to the Company’s ability to generate future taxable income in its conclusion of the need for a full valuation allowance.  Any reversal of the Company’s valuation allowance will favorably impact its results of operations in the period of reversal.  The Company is currently unable to determine whether or when that reversal might occur, but it will continue to assess the realizability of its deferred tax assets and will adjust the valuation allowance if it is more likely than not that all or a portion of the deferred tax assets will become realizable in the future.  The Company has significant net operating loss carry forwards and other tax attributes that are available to offset projected taxable income and current taxes payable, if any, for the year ending January 28, 2023.  The deferred tax impact resulting from the utilization of the net operating loss carry forwards and other tax attributes will be offset by a reduction in the valuation allowance. As of January 28, 2023, the Company had a net operating loss carry forward of $369.1 million for federal income tax purposes and approximately $224.4 million for state income tax purposes that expire at various times through 2040 and are subject to certain limitations and statutory expiration periods.  The Company has not changed its overall conclusion with respect to the need for a valuation allowance against its net deferred tax assets, which remain fully reserved.
v3.23.2
Commitments and Contingencies
 6 Months Ended
Jul. 29, 2023
Commitments and Contingencies [Abstract]  
Commitments and Contingencies
Note 13. Commitments and Contingencies
Legal Proceedings
The Company is subject to legal proceedings and claims that have arisen in the ordinary course of its business and have not been finally adjudicated.  Although there can be no assurance as to the ultimate disposition of these matters, it is management’s opinion, based upon the information available at this time, that the expected outcome of these matters, individually and in the aggregate, will not have a material adverse effect on the results of operations and financial condition of the Company. As a result, the liability for the cases listed below is remote.
On June 18, 2021, Vijuve Inc. filed a lawsuit against Kaspien Inc. in the United States District Court for the Eastern District of Washington (Case No. 2:21-cv-00192-SAB) concerning a Retailer Agreement that the parties entered into in September of 2020. Vijuve manufactures skin care products and face massagers. The parties agreed that Kaspien would sell Vijuve’s products on Amazon. The complaint alleged that Kaspien breached the Retailer Agreement when it declined to acquiesce to Vijuve’s demand that Kaspien purchase over $700,000 of products. In total, Vijuve sought $774,000 in damages. Kaspien denied that it breached the agreement and filed various counterclaims. Kaspien sought at least $229,000 from Vijuve for breach of contract and/or specific performance. On June 26, 2023, the Court granted our motion for summary judgment and dismissed Vijuve’s claim against Kaspien.

Contingent Value Rights
 
On March 30, 2020, the Company entered into the Contingent Value Rights Agreement (the “CVR Agreement”), pursuant to which the Related Party Entities received contingent value rights (“CVRs”) representing the contractual right to receive cash payments from the Company in an amount equal, in the aggregate, to 19.9% of the proceeds (10.35% for Alimco, 1.90% for Kick-Start, and 7.64% for RJHDC) received by the Company in respect of certain intercompany indebtedness owing to it by Kaspien and/or its equity interest in Kaspien. The Company does not anticipate these contingencies being met in Fiscal 2023.

On March 2, 2022, the Company entered into a Contingent Value Rights Agreement (the “Second CVR Agreement”) with the Tranche B Lender under the Subordinated Loan Agreement, pursuant to which the Tranche B Lender received contingent value rights (“Second CVRs”) representing the contractual right to receive cash payments from the Company in an amount equal, in the aggregate, to 9.0% of the proceeds received by the Company in respect of certain distributions by the Company or Kaspien; recapitalizations or financings of the Company or Kaspien (with appropriate carve out for trade financing in the ordinary course); repayment of intercompany indebtedness owing to the Company by Kaspien; or sale or transfer of any stock of the Company or Kaspien.

The CVRs terminate upon the earlier to occur of (i) certain consolidations, mergers or similar extraordinary events involving Kaspien (and, if applicable, the making of a cash payment by the Company to the Lenders pursuant to the CVR Agreement in connection therewith) and (ii) March 2, 2032.
v3.23.2
Nature of Operations (Policies)
 6 Months Ended
Jul. 29, 2023
Nature of Operations [Abstract]  
Nature of Operations
Kaspien Holdings Inc., which, together with its consolidated subsidiaries, is referred to herein as “Kaspien”, “the Company”, “we”, “us” and “our”, was incorporated in New York in 1972. We own 100% of the outstanding common stock of Kaspien Inc, through which our principal operations are conducted. Kaspien is a third-party marketplace retailer. The Company leverages in-house expertise, technology, and services to generate revenue through marketplace transactions. Kaspien provides account management, brand development, listings management, data reporting, joint business planning, and comprehensive marketing support services to our vendor partners.  Our target partners are enterprise-level large growth brands that derive margins based on pricing.

We are guided by 5 core principles:
•
We are partner obsessed. Our customers are our partners. Every decision is focused on building mutually beneficial relationships that deliver results.

•
We are insights driven. We make data actionable. Our curiosity drives us to discover opportunities early and often.

•
We create simplicity. We challenge the status quo. We take the complicated and simplify it.

•
We take ownership. We make things happen. We hold ourselves accountable and have a bias for action.

•
We empower each other. We welcome and learn from diverse experiences. Our empathy ignites innovation and empowers meaningful change.

On June 6, 2023, Kaspien entered into an Asset Purchase Agreement (the “Asset Purchase Agreement”), pursuant to which Kaspien sold substantially all of the assets of and certain of the liabilities relating to Kaspien’s agency business model through which Kaspien provides support services for account management, media planning, media analytics, search strategy, business planning, and data reporting to its partners (the “Business” and the transaction, the “Transaction”). The Transaction closed on June 6, 2023.
Liquidity and Cash Flows
Liquidity and Cash Flows:
The Company’s primary sources of liquidity are its borrowing capacity under its Credit Facility, available cash and cash equivalents, and to a lesser extent, cash generated from operations. Our cash requirements relate primarily to working capital needed to operate Kaspien, including funding operating expenses, the purchase of inventory and capital expenditures.
 
The Company incurred a net loss of $3.3 million and $8.8 million for the twenty-six weeks ended July 29, 2023 and July 30, 2022, respectively.  The decrease in the net loss was primarily attributable to a decrease in sales and gross margin. In addition, the Company has an accumulated deficit of $143.3 million as of July 29, 2023 and net cash used in operating activities for the twenty-six weeks ended July 29, 2023 was $0.7 million. Net cash used in operating activities for the twenty-six weeks ended July 30, 2022 was $5.9 million.

As disclosed in the Company’s Annual Report on Form 10-K filed April 28, 2023, the Company experienced negative cash flows from operations during fiscal 2022 and 2021 and we expect to incur net losses in fiscal 2023.

Our ability to achieve profitability and meet future liquidity needs and capital requirements will depend upon numerous factors, including the timing and amount of our revenue; the timing and amount of our operating expenses; the timing and costs of working capital needs; and successful implementation of our strategy and planned activities. There can be no assurance that we will be successful in further implementing our business strategy or that the strategy, including the completed initiatives, will be successful in sustaining acceptable levels of sales growth and profitability. The condensed consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.
The unaudited condensed consolidated financial statements for the twenty-six weeks ended July 29, 2023 were prepared pursuant to the rules and regulations of the Securities and Exchange Commission. The information furnished in these unaudited condensed consolidated financial statements reflects all normal, recurring adjustments which, in the opinion of management, are necessary for the fair presentation of such financial statements. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The ability of the Company to meet its liabilities and to continue as a going concern is dependent on improved profitability, the strategic initiatives for Kaspien and the availability of future funding. Based on recurring losses from operations, negative cash flows from operations, the expectation of continuing operating losses for the foreseeable future, and uncertainty with respect to any available future funding, the Company has concluded that there is substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
As of July 29, 2023, we had cash and cash equivalents of $0.3 million, a net working deficit of $0.7 million, and $8.8 in borrowings on our revolving credit facility, as further discussed below.
As of January 28, 2023, the Company had borrowings of $8.8 million under the Credit Facility. As of April 29, 2023 and April 30, 2022, the Company had no outstanding letters of credit. The Company had $3.4 million and $7.7 million available for borrowing under the Credit Facility as of  July 29, 2023 and July 30, 2022, respectively.
Credit Facility
Credit Facility
On February 20, 2020, Kaspien Inc. entered into a Loan and Security Agreement (as subsequently amended, the “Loan Agreement”) with Eclipse Business Capital LLC (f/k/a Encina Business Credit, LLC) (“Eclipse”), as administrative agent, under which the lenders party thereto committed to provide up to $25 million in loans under a four-year, secured revolving credit facility (the “Credit Facility”).

On March 30, 2020, the Company and Kaspien Inc. (the “Loan Parties”) entered into Amendment No. 1 to the Loan Agreement (the “Amendment”). Pursuant to the Amendment, among other things, (i) the Company was added as “Parent” under the Amended Loan Agreement, (ii) the Company granted a first priority security interest in substantially all of the assets of the Company, including inventory, accounts receivable, cash and cash equivalents and certain other collateral, and (iii) the Loan Agreement was amended to (a) permit the incurrence of certain subordinated indebtedness under the Subordinated Loan Agreement (as defined below) and (b) limit the Company’s ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.


On April 7, 2021, the Loan Parties entered into Amendment No. 2 to the Loan Agreement (the “Second Amendment”. Pursuant to the Second Amendment, the In-Transit Inventory Sublimit (as defined in the Loan Agreement) was increased from $2,000,000 to $2,500,000.

On September 17, 2021, the Loan Parties entered into Amendment No. 3 to the Loan Agreement (the “Third Amendment”). Pursuant to the Third Amendment, among other things, (i) the maturity of the Credit Facility was extended to February 20, 2024, and the early termination fees were accordingly reset; (ii) the LIBOR floor was reduced to 1.00%; (iii) up to $4,000,000 of acquisitions are now allowed without Eclipse’s consent, subject to satisfaction of various conditions, including the Company having a trailing twelve month fixed charge coverage ratio of 1.20x and Excess Availability greater than the greater of (x) 20% of the average Borrowing Base for each 30 day period immediately prior to, and pro forma for, the purchase and (y) $1,500,000.


On March 2, 2022, the Loan Parties entered into Amendment No. 4 to the Loan Agreement (the “Fourth Amendment”). Pursuant to the Fourth Amendment, among other things, the Credit Facility was amended to permit the incurrence of the Additional Subordinated Loan (as defined below) under the Subordinated Loan Agreement (as defined below).



On November 1, 2022, the Loan Parties entered into Amendment No. 5 to the loan agreement (the “Fifth Amendment”). Pursuant to the Fifth Amendment, the Credit Facility was amended to replace LIBOR with the Secured Overnight Funding Rate (“SOFR”).

As of July 29, 2023 and July 30, 2022, the Company had borrowings of $8.8 and $3.9 million under the Credit Facility, respectively.

Subordinated Debt Agreement
On March 30, 2020, the Loan Parties entered into a Subordinated Loan and Security Agreement (the “Subordinated Loan Agreement”) with the lenders party thereto from time to time (the “Lenders”) and TWEC Loan Collateral Agent, LLC (the “Collateral Agent”), as collateral agent for the Lenders, pursuant to which the Lenders made a $5.2 million secured term loan (the “Subordinated Loan”) to Kaspien with a scheduled maturity date of May 22, 2023. As of July 29, 2023, unamortized debt issuance costs of $0.1 million are included in “Long Term Debt” on the unaudited condensed consolidated balance sheet.
Directors Jonathan Marcus, Thomas Simpson, and Michael Reickert are the chief executive officer of Alimco Re Ltd. (“Alimco”), the managing member of Kick-Start III, LLC and Kick-Start IV, LLC (“Kick-Start”), and a trustee of the Robert J. Higgins TWMC Trust (the “Trust”), an affiliate of RJHDC, LLC (“RJHDC” and together with Alimco and Kick-Start, “Related Party Entities”), respectively.  The Related Party Entities are parties to the Subordinated Loan Agreement.


Amendment No. 2 to Subordinated Loan and Security Agreement



On March 2, 2022, the Loan Parties entered into that certain Amendment No. 2 to Subordinated Loan and Security Agreement (“Amendment No. 2”) with the “Lenders and the Collateral Agent. Pursuant to Amendment No. 2, among other things, Alimco Re Ltd. (the “Tranche B Lender”) made an additional $5,000,000 secured term loan (the “Additional Subordinated Loan”) with a scheduled maturity date of March 31, 2024, which is the same maturity date as the existing loans under the Subordinated Loan Agreement.

Interest on the Additional Subordinated Loan accrues, subject to certain terms and conditions under the Subordinated Loan Agreement, at the rate of fifteen percent (15.0%) per annum, compounded on the last day of each calendar quarter by becoming a part of the principal amount of the Additional Subordinated Loan.


The Additional Subordinated Loan is also secured by a second priority security interest in substantially all of the assets of the Loan Parties, including inventory, accounts receivable, cash and cash equivalents and certain other collateral of the borrowers and guarantors under the Subordinated Loan Agreement. The Company will provide a limited guarantee of Kaspien’s obligations under the Additional Subordinated Loan.



Among other things, the Subordinated Loan Agreement limits the Loan Parties’ ability to incur additional indebtedness, create liens, make investments, make restricted payments or specified payments and merge or acquire assets.


The Subordinated Loan Agreement contains customary events of default, including, but not limited to, payment defaults, breaches of representations and warranties, covenant defaults, cross-defaults to other obligations, customary ERISA defaults, certain events of bankruptcy and insolvency, judgment defaults, the invalidity of liens on collateral, change in control, cessation of business or the liquidation of material assets of the borrowers and guarantors thereunder taken as a whole and the occurrence of an uninsured loss to a material portion of collateral.


The Loan Parties paid certain customary fees and expenses in connection with the Additional Subordinated Loan and Amendment No. 2.


In addition to the aforementioned current sources of existing working capital, the Company may explore certain other strategic alternatives that may become available to the Company, as well continuing our efforts to generate additional sales and increase margins. However, at this time the Company has no commitments to obtain any additional funds, and there can be no assurance such funds will be available on acceptable terms or at all, should we require such additional funds. If the Company is unable to improve its operations, it may be required to obtain additional funding, and the Company’s financial condition and results of operations may be materially adversely affected.
Furthermore, broad market and industry factors may seriously harm the market price of our common stock, regardless of our operating performance, and may adversely impact our ability to raise additional funds, should we require such additional funds.
v3.23.2
Recently Adopted Accounting Pronouncements (Policies)
 6 Months Ended
Jul. 29, 2023
Recently Adopted Accounting Pronouncements [Abstract]  
Recently Adopted Accounting Pronouncements
In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which introduced an expected credit loss model for the impairment of financial assets measured at amortized cost. The model replaces the probable, incurred loss model for those assets and instead, broadens the information an entity must consider in developing its expected credit loss estimate for assets measured at amortized cost. This standard will be effective for smaller reporting companies for fiscal years beginning after December 15, 2022. We have completed our evaluation and have determined that the update will not have a material impact on our consolidated financial condition, results of operations, or cash flows.

In March 2020, the FASB issued ASU No. 2020-04, “Reference Rate Reform (Topic 848): facilitation of the Effects of Reference Rate Reform on Financial Reporting” (“ASU 2020-04”). ASU 2020-04 provides optional expedients and exceptions for applying U.S. GAAP to contract modifications and hedging relationships that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU 2020-04 provides, among other things, guidance that modifications of contracts within the scope of Topic 470, Debt, should be accounted for by prospectively adjusting the effective interest rate; modifications of contracts within the scope of Topic 840, Leases, should be accounted for as a continuation of the existing contract; and, changes in the critical terms of hedging relationships, caused by reference rate reform, should not result in the de-designation of the instrument, provided certain criteria are met. The Company’s exposure to LIBOR rates includes its credit facility. The amendments are effective as of March 12, 2020 through December 31, 2022. We have completed our evaluation and have determined that the update will not have a material impact on our consolidated financial condition, results of operations, or cash flows.

Recent accounting pronouncements pending adoption not discussed above are either not applicable or are not expected to have a material impact on our consolidated financial condition, results of operations, or cash flows.
v3.23.2
Restricted Cash (Tables)
 6 Months Ended
Jul. 29, 2023
Restricted Cash [Abstract]  
Cash, Cash Equivalents and Restricted Cash
A summary of cash, cash equivalents and restricted cash is as follows (amounts in thousands):

   
July 29,
    
January 28,
    
July 30,
  
     2023     2023     2022
 
Cash and cash equivalents
  
$
282
    
$
1,130
    
$
1,309
  
Restricted cash
    
2,473
      
2,496
      
3,031
  
Total cash, cash equivalents and restricted cash
  
$
2,755
    
$
3,626
    
$
4,340
  
v3.23.2
Stock Based Compensation (Tables)
 6 Months Ended
Jul. 29, 2023
Stock Based Compensation [Abstract]  
Stock Option Activity Under Stock Award Plans
The following table summarizes stock award activity during the thirteen weeks ended July 29, 2023:

    Employee Stock Award Plans
 
   
Number of
Shares
Subject To
Option
   
Weighted
Average
Exercise
Price
   
Weighted
Average
Remaining
Contractual
Term
   
Other
Share
Awards (1)
    
Weighted
Average
Grant Fair
Value
 
Balance January 28, 2023
    
123,642
    
$
6.00
      
7.5
       19,500
     $ 18.35  
Granted
    
-
      
-
      
-
       60,000       0.61  
Forfeited
    
(7,637
)
    
(9.01
)
    
-
       -       -  
Canceled
    
(500
)
    
(97.40
)
    
-
       -       -  
Exercised
    
-
      
-
      
-
       -       -  
Balance July 29, 2023
    
115,505
    
$
5.79
      
8.4
       79,500     $ 4.96  
Exercisable July 29, 2023
    
35,042
    
$
13.37
      
7.0
       -       -  

 (1) Other Share Awards include deferred shares granted to executives and directors.
v3.23.2
Shareholders' Equity (Deficit) (Tables)
 6 Months Ended
Jul. 29, 2023
Shareholders' Equity [Abstract]  
Summary of Warrant Activity
The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, as of April 29, 2023:

Exercise
    
Number
  
Price
    
Outstanding
  
$
0.01
      
325,126
  
$
3.13
      
2,457,160
  
         
2,782,286
  
v3.23.2
Defined Benefit Plan (Tables)
 6 Months Ended
Jul. 29, 2023
Defined Benefit Plan [Abstract]  
Net Periodic Pension Cost

The following represents the components of the net periodic pension cost related to the Company’s SERP for the respective periods:


   
Thirteen Weeks Ended
    
Twenty-six Weeks Ended
  
(amounts in thousands)
 
July 29,
    
July 30,
    
July 29,
    
July 30,

  2023
     2022
     2023
     2022
  
                         
Interest cost
  
$
139
    
$
89
    
$
278
    
$
178
  
Net periodic pension cost
  
$
139
    
$
89
    
$
278
    
$
178
  
v3.23.2
Nature of Operations, Summary (Details)
 6 Months Ended
Jul. 29, 2023
Kaspien Inc. [Member]  
Subsidiary Information [Abstract]  
Ownership interest 100.00%
v3.23.2
Nature of Operations, Liquidity and Cash Flows (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jul. 29, 2023
Jul. 30, 2022
Jul. 29, 2023
Jul. 30, 2022
Apr. 29, 2023
Jan. 28, 2023
Apr. 30, 2022
Liquidity and Cash Flows [Abstract]              
Net loss $ (1,161) $ (4,416) $ (3,312) $ (8,846)      
Accumulated deficit (143,250) (129,740) (143,250) (129,740)   $ (139,938)  
Net cash used in operating activities     (719) (5,893)      
Cash and cash equivalents 282 1,309 282 1,309   1,130  
Net working capital (deficit) (700)   (700)        
Borrowings 8,797 3,855 8,797 3,855   8,812  
Credit Facility [Member]              
Liquidity and Cash Flows [Abstract]              
Borrowings 8,800 3,900 8,800 3,900   $ 8,800  
Outstanding letters of credit         $ 0   $ 0
Available borrowings $ 3,400 $ 7,700 $ 3,400 $ 7,700      
v3.23.2
Nature of Operations, Credit Facility and Subordinated Debt Agreement (Details)
 6 Months Ended
Sep. 17, 2021
USD ($)
Jul. 29, 2023
USD ($)
Jan. 28, 2023
USD ($)
Oct. 29, 2022
USD ($)
Jul. 30, 2022
USD ($)
Mar. 02, 2022
USD ($)
Apr. 07, 2021
USD ($)
Apr. 06, 2021
USD ($)
Mar. 30, 2020
USD ($)
Feb. 20, 2020
USD ($)
Credit Facility [Abstract]                    
Short-term borrowings   $ 8,797,000 $ 8,812,000   $ 3,855,000          
Subordinated Loan Agreement [Member]                    
Credit Facility [Abstract]                    
Maturity date   Mar. 31, 2024                
Secured term loan           $ 5,000,000        
Unamortized debt issuance costs   $ 100,000                
Interest rate           15.00%        
Kaspien Inc. [Member]                    
Credit Facility [Abstract]                    
Unamortized debt issuance costs       $ 100,000            
Kaspien Inc. [Member] | Subordinated Loan Agreement [Member]                    
Credit Facility [Abstract]                    
Secured term loan                 $ 5,200,000  
Credit Facility [Member]                    
Credit Facility [Abstract]                    
Short-term borrowings   $ 8,800,000 $ 8,800,000   $ 3,900,000          
Credit Facility [Member] | Kaspien Inc. [Member]                    
Credit Facility [Abstract]                    
Loan amount             $ 2,500,000 $ 2,000,000    
Term of loan   4 years                
Maturity date   Feb. 20, 2024                
Trailing period for fixed charge coverage ratio   12 months                
Fixed charge coverage ratio 1.2                  
Percentage of average borrowing base for excess availability 20.00%                  
Period for borrowing base   30 days                
Minimum excess availability amount $ 1,500,000                  
Credit Facility [Member] | Kaspien Inc. [Member] | LIBOR [Member]                    
Credit Facility [Abstract]                    
Debt instrument, basis spread on variable rate 1.00%                  
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member]                    
Credit Facility [Abstract]                    
Loan amount                   $ 25,000,000
Acquisitions value allowed without consent $ 4,000,000                  
v3.23.2
Depreciation and Amortization (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jul. 29, 2023
Jul. 30, 2022
Jul. 29, 2023
Jul. 30, 2022
Depreciation and Amortization [Abstract]        
Depreciation and amortization $ 0.2 $ 0.3 $ 0.4 $ 0.6
v3.23.2
Restricted Cash (Details) - USD ($)
$ in Thousands
Jul. 29, 2023
Jan. 28, 2023
Jul. 30, 2022
Jan. 29, 2022
Restricted Cash and Cash Equivalents [Abstract]        
Restricted cash, current asset $ 1,158 $ 1,158 $ 1,158  
Cash Equivalents and Restricted Cash [Abstract]        
Cash and cash equivalents 282 1,130 1,309  
Restricted cash 2,473 2,496 3,031  
Total cash, cash equivalents and restricted cash 2,755 $ 3,626 $ 4,340 $ 4,823
Rabbi Trust [Member]        
Restricted Cash and Cash Equivalents [Abstract]        
Restricted cash, current asset 1,200      
Restricted cash, long-term asset 1,300      
Cash Equivalents and Restricted Cash [Abstract]        
Restricted cash $ 2,500      
v3.23.2
Debt, Credit Facility (Details)
 6 Months Ended
Sep. 17, 2021
USD ($)
Jul. 29, 2023
USD ($)
Jan. 28, 2023
USD ($)
Oct. 29, 2022
USD ($)
Jul. 30, 2022
USD ($)
Apr. 07, 2021
USD ($)
Apr. 06, 2021
USD ($)
Feb. 20, 2020
USD ($)
New Credit Facility [Abstract]                
Short-term borrowings   $ 8,797,000 $ 8,812,000   $ 3,855,000      
Other Assets [Member]                
New Credit Facility [Abstract]                
Unamortized debt issuance costs   $ 100,000            
Kaspien Inc. [Member]                
New Credit Facility [Abstract]                
Unamortized debt issuance costs       $ 100,000        
New Credit Facility [Member] | Kaspien Inc. [Member]                
New Credit Facility [Abstract]                
Term of loan   4 years            
New Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member]                
New Credit Facility [Abstract]                
Loan amount               $ 25,000,000
Credit Facility [Member]                
New Credit Facility [Abstract]                
Short-term borrowings   $ 8,800,000 $ 8,800,000   $ 3,900,000      
Credit Facility [Member] | Kaspien Inc. [Member]                
New Credit Facility [Abstract]                
Loan amount           $ 2,500,000 $ 2,000,000  
Term of loan   4 years            
Maturity date   Feb. 20, 2024            
Trailing period for fixed charge coverage ratio   12 months            
Fixed charge coverage ratio 1.2              
Percentage of average borrowing base for excess availability 20.00%              
Period for borrowing base   30 days            
Minimum excess availability amount $ 1,500,000              
Credit Facility [Member] | Kaspien Inc. [Member] | LIBOR [Member]                
New Credit Facility [Abstract]                
Debt instrument, basis spread on variable rate 1.00%              
Credit Facility [Member] | Minimum [Member] | Kaspien Inc. [Member] | SOFR [Member]                
New Credit Facility [Abstract]                
Debt instrument, basis spread on variable rate   4.00%            
Credit Facility [Member] | Minimum [Member] | Kaspien Inc. [Member] | Base Rate [Member]                
New Credit Facility [Abstract]                
Debt instrument, basis spread on variable rate   3.00%            
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member]                
New Credit Facility [Abstract]                
Loan amount               25,000,000
Swing line loans               $ 5,000,000
Acquisitions value allowed without consent $ 4,000,000              
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member] | SOFR [Member]                
New Credit Facility [Abstract]                
Debt instrument, basis spread on variable rate   4.50%            
Credit Facility [Member] | Maximum [Member] | Kaspien Inc. [Member] | Base Rate [Member]                
New Credit Facility [Abstract]                
Debt instrument, basis spread on variable rate   3.50%            
v3.23.2
Debt, Subordinated Loan Agreement (Details) - USD ($)
 6 Months Ended
Jul. 29, 2023
Apr. 29, 2023
Oct. 29, 2022
Mar. 02, 2022
Mar. 30, 2020
Subordinated Loan Agreement [Abstract]          
Warrants issued to purchase common stock (in shares)   2,782,286      
Kaspien Inc. [Member]          
Subordinated Loan Agreement [Abstract]          
Unamortized debt issuance costs     $ 100,000    
Subordinated Loan [Member]          
Subordinated Loan Agreement [Abstract]          
Unamortized debt issuance costs     $ 100,000    
Interest rate         12.00%
Warrants issued to purchase common stock (in shares) 244,532        
Warrants exercise price (in dollars per share) $ 0.01        
Value of warrants $ 800,000        
Number of remaining outstanding warrants (in shares) 5,126        
Subordinated Loan [Member] | Kaspien Inc. [Member]          
Subordinated Loan Agreement [Abstract]          
Secured term loan         $ 5,200,000
Maturity date Mar. 31, 2024        
Subordinated Loan [Member] | Alimco [Member]          
Subordinated Loan Agreement [Abstract]          
Warrants issued to purchase common stock (in shares) 127,208        
Subordinated Loan [Member] | Kick-Start [Member]          
Subordinated Loan Agreement [Abstract]          
Warrants issued to purchase common stock (in shares) 23,401        
Subordinated Loan [Member] | RJHDC [Member]          
Subordinated Loan Agreement [Abstract]          
Warrants issued to purchase common stock (in shares) 93,923        
Additional Subordinated Loan [Member]          
Subordinated Loan Agreement [Abstract]          
Secured term loan       $ 5,000,000  
Unamortized debt issuance costs $ 600,000        
Interest rate       15.00%  
Warrants issued to purchase common stock (in shares)       320,000  
Warrants exercise price (in dollars per share)       $ 0.01  
Value of warrants       $ 1,600,000  
Additional Subordinated Loan [Member] | Kaspien Inc. [Member]          
Subordinated Loan Agreement [Abstract]          
Maturity date Mar. 31, 2024        
v3.23.2
Stock Based Compensation (Details)
 6 Months Ended 12 Months Ended
Jul. 29, 2023
USD ($)
Plan
$ / shares
shares
Jan. 28, 2023
$ / shares
shares
Stock Awards [Abstract]    
Number of employee stock award plans | Plan 4  
Weighted Average Grant Fair Value [Abstract]    
Intrinsic value of stock awards outstanding | $ $ 0  
Intrinsic value of stock awards exercisable | $ $ 0  
Employee Stock Award Plans [Member]    
Number of Shares Subject to Option [Roll Forward]    
Balance (in shares) 123,642  
Granted (in shares) 0  
Forfeited (in shares) (7,637)  
Canceled (in shares) (500)  
Exercised (in shares) 0  
Balance (in shares) 115,505 123,642
Exercisable (in shares) 35,042  
Weighted Average Exercise Price [Abstract]    
Balance (in dollars per share) | $ / shares $ 6  
Granted (in dollars per share) | $ / shares 0  
Forfeited (in dollars per share) | $ / shares (9.01)  
Canceled (in dollars per share) | $ / shares (97.4)  
Exercised (in dollars per share) | $ / shares 0  
Balance (in dollars per share) | $ / shares 5.79 $ 6
Exercisable (in dollars per share) | $ / shares $ 13.37  
Weighted Average Remaining Contractual Term [Abstract]    
Weighted average remaining contractual term 8 years 4 months 24 days 7 years 6 months
Exercisable 7 years  
Other Share Awards [Abstract]    
Balance (in shares) [1] 19,500  
Granted (in shares) [1] 60,000  
Forfeited (in shares) [1] 0  
Cancelled (in shares) [1] 0  
Exercised (in shares) [1] 0  
Balance (in shares) [1] 79,500 19,500
Exercisable (in shares) [1] 0  
Weighted Average Grant Fair Value [Abstract]    
Balance (in dollars per share) | $ / shares $ 18.35  
Granted (in dollars per share) | $ / shares 0.61  
Forfeited (in dollars per share) | $ / shares 0  
Canceled (in dollars per share) | $ / shares 0  
Exercised (in dollars per share) | $ / shares 0  
Balance (in dollars per share) | $ / shares 4.96 $ 18.35
Exercisable (in dollars per share) | $ / shares $ 0  
New Plan [Member]    
Stock Awards [Abstract]    
Equity awards authorized for issuance (in shares) 500,000  
Equity awards granted and are outstanding (in shares) 195,005  
Equity awards vested and exercisable (in shares) 35,042  
Shares available for future grants (in shares) 391,137  
[1] Other Share Awards include deferred shares granted to executives and directors.
v3.23.2
Shareholders' Equity (Deficit) (Details) - USD ($)
 6 Months Ended
Jul. 12, 2022
Jul. 29, 2023
Apr. 29, 2023
Shareholders' Equity [Abstract]      
Proceeds from equity   $ 7,100,000  
Offering expenses   $ 900,000  
Outstanding Warrants to Purchase Common Stock [Abstract]      
Number Outstanding (in shares)     2,782,286
PIPE Purchase Agreement [Member]      
Shareholders' Equity [Abstract]      
Proceeds from issuance of private placement $ 6,000,000    
PIPE Purchase Agreement [Member] | Pre-Funded Warrants [Member]      
Shareholders' Equity [Abstract]      
Warrant exercisable (in shares) 1    
Outstanding Warrants to Purchase Common Stock [Abstract]      
Exercise Price (in dollars per share)     $ 0.01
Number Outstanding (in shares) 1,818,182   325,126
PIPE Purchase Agreement [Member] | Investor Warrants [Member]      
Shareholders' Equity [Abstract]      
Warrant exercisable (in shares) 1    
Share price (in dollars per share) $ 3.3    
Warrants exercise price (in dollars per share) $ 3.13    
Warrants expiration period   5 years  
Outstanding Warrants to Purchase Common Stock [Abstract]      
Exercise Price (in dollars per share)     $ 3.13
Number Outstanding (in shares)     2,457,160
Registered Purchase Agreement [Member]      
Shareholders' Equity [Abstract]      
Warrants exercise price (in dollars per share)   $ 2.77  
Proceeds from equity $ 2,000,000    
Intrinsic value of warrants   $ 60,000  
Weighted average remaining term of warrants   4 years  
Registered Purchase Agreement [Member] | Pre-Funded Warrants [Member]      
Shareholders' Equity [Abstract]      
Warrant exercisable (in shares) 1    
Outstanding Warrants to Purchase Common Stock [Abstract]      
Number Outstanding (in shares) 638,978    
v3.23.2
Defined Benefit Plan (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jul. 29, 2023
Jul. 30, 2022
Jul. 29, 2023
Jul. 30, 2022
Net Periodic Pension Cost [Abstract]        
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]     Interest Income (Expense), Net  
Supplemental Executive Retirement Plan [Member]        
Contributions by Employer [Abstract]        
Cash contributions by employer $ 0      
Expected cash contributions by employer 1,200   $ 1,200  
Net Periodic Pension Cost [Abstract]        
Interest cost 139 $ 89 278 $ 178
Net periodic pension cost $ 139 $ 89 $ 278 $ 178
v3.23.2
Basic and Diluted Loss Per Share (Details) - shares
shares in Millions
 3 Months Ended 6 Months Ended
Jul. 29, 2023
Jul. 29, 2023
Basic and Diluted Loss Per Share [Abstract]    
Total anti-dilutive stock awards (in shares) 0.1 0.1
Warrant [Member]    
Basic and Diluted Loss Per Share [Abstract]    
Total anti-dilutive stock awards (in shares) 2.8 2.8
v3.23.2
Income Taxes (Details) - USD ($)
$ in Millions
 6 Months Ended
Jul. 29, 2023
Jan. 28, 2023
Federal [Member]    
Operating Loss Carryforwards Components [Abstract]    
Net operating loss carryforwards   $ 369.1
Operating loss carryforward expiration year 2040  
State [Member]    
Operating Loss Carryforwards Components [Abstract]    
Net operating loss carryforwards   $ 224.4
Operating loss carryforward expiration year 2040  
v3.23.2
Commitments and Contingencies (Details) - USD ($)
Jul. 18, 2022
Jun. 18, 2021
Mar. 02, 2022
Mar. 30, 2020
Legal Proceedings [Abstract]        
Percentage of CVR to receive cash payment     9.00% 19.90%
Alimco [Member]        
Legal Proceedings [Abstract]        
Percentage of CVR to receive cash payment       10.35%
Kick-Start [Member]        
Legal Proceedings [Abstract]        
Percentage of CVR to receive cash payment       1.90%
RJHDC [Member]        
Legal Proceedings [Abstract]        
Percentage of CVR to receive cash payment       7.64%
Vijuve Inc. [Member]        
Legal Proceedings [Abstract]        
Purchase of product expected as part of agreement   $ 700,000    
Damages sought value   $ 774,000    
Vijuve Inc. [Member] | Minimum [Member]        
Legal Proceedings [Abstract]        
Damages claims value $ 229,000      
Kaspien (NASDAQ:KSPN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Kaspien Charts.
Kaspien (NASDAQ:KSPN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Kaspien Charts.